<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:59:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9119485" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9119485</identifier>
        <datestamp>2022-05-20</datestamp>
        <setSpec>ploscomp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS Comput Biol</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS Computational Biology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1553-734X</issn>
              <issn pub-type="epub">1553-7358</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9119485</article-id>
              <article-id pub-id-type="pmcid">PMC9119485</article-id>
              <article-id pub-id-type="pmc-uid">9119485</article-id>
              <article-id pub-id-type="pmid">35533200</article-id>
              <article-id pub-id-type="pmid">35533200</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1010079</article-id>
              <article-id pub-id-type="publisher-id">PCOMPBIOL-D-21-01786</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Brain</subject>
                      <subj-group>
                        <subject>Locus Coeruleus</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Brain</subject>
                      <subj-group>
                        <subject>Locus Coeruleus</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Neurodegenerative Diseases</subject>
                      <subj-group>
                        <subject>Movement Disorders</subject>
                        <subj-group>
                          <subject>Parkinson Disease</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Neurodegenerative Diseases</subject>
                      <subj-group>
                        <subject>Movement Disorders</subject>
                        <subj-group>
                          <subject>Parkinson Disease</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Cognitive Science</subject>
                      <subj-group>
                        <subject>Cognitive Psychology</subject>
                        <subj-group>
                          <subject>Perception</subject>
                          <subj-group>
                            <subject>Sensory Perception</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Cognitive Psychology</subject>
                      <subj-group>
                        <subject>Perception</subject>
                        <subj-group>
                          <subject>Sensory Perception</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Sensory Perception</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drug Interactions</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Chemistry</subject>
                    <subj-group>
                      <subject>Chemical Compounds</subject>
                      <subj-group>
                        <subject>Organic Compounds</subject>
                        <subj-group>
                          <subject>Amines</subject>
                          <subj-group>
                            <subject>Catecholamines</subject>
                            <subj-group>
                              <subject>Dopamine</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Chemistry</subject>
                    <subj-group>
                      <subject>Organic Chemistry</subject>
                      <subj-group>
                        <subject>Organic Compounds</subject>
                        <subj-group>
                          <subject>Amines</subject>
                          <subj-group>
                            <subject>Catecholamines</subject>
                            <subj-group>
                              <subject>Dopamine</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurotransmitters</subject>
                        <subj-group>
                          <subject>Biogenic Amines</subject>
                          <subj-group>
                            <subject>Catecholamines</subject>
                            <subj-group>
                              <subject>Dopamine</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurotransmitters</subject>
                        <subj-group>
                          <subject>Biogenic Amines</subject>
                          <subj-group>
                            <subject>Catecholamines</subject>
                            <subj-group>
                              <subject>Dopamine</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Hormones</subject>
                      <subj-group>
                        <subject>Catecholamines</subject>
                        <subj-group>
                          <subject>Dopamine</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Magnetic Resonance Imaging</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Imaging Techniques</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Magnetic Resonance Imaging</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Radiology and Imaging</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Magnetic Resonance Imaging</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Social Sciences</subject>
                  <subj-group>
                    <subject>Psychology</subject>
                    <subj-group>
                      <subject>Behavior</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drugs</subject>
                      <subj-group>
                        <subject>Levodopa</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurochemicals</subject>
                        <subj-group>
                          <subject>Levodopa</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurochemicals</subject>
                        <subj-group>
                          <subject>Levodopa</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes</article-title>
                <alt-title alt-title-type="running-head">Noradrenergic mechanisms of apathy in Parkinson’s disease</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0092-3289</contrib-id>
                  <name>
                    <surname>Hezemans</surname>
                    <given-names>Frank H.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4652-7727</contrib-id>
                  <name>
                    <surname>Wolpe</surname>
                    <given-names>Noham</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5698-6364</contrib-id>
                  <name>
                    <surname>O’Callaghan</surname>
                    <given-names>Claire</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2529-7755</contrib-id>
                  <name>
                    <surname>Ye</surname>
                    <given-names>Rong</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0404-4399</contrib-id>
                  <name>
                    <surname>Rua</surname>
                    <given-names>Catarina</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9695-0702</contrib-id>
                  <name>
                    <surname>Jones</surname>
                    <given-names>P. Simon</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0813-0670</contrib-id>
                  <name>
                    <surname>Murley</surname>
                    <given-names>Alexander G.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3813-0882</contrib-id>
                  <name>
                    <surname>Holland</surname>
                    <given-names>Negin</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7292-1859</contrib-id>
                  <name>
                    <surname>Regenthal</surname>
                    <given-names>Ralf</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <xref rid="aff008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3178-6363</contrib-id>
                  <name>
                    <surname>Tsvetanov</surname>
                    <given-names>Kamen A.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barker</surname>
                    <given-names>Roger A.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="aff011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williams-Gray</surname>
                    <given-names>Caroline H.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robbins</surname>
                    <given-names>Trevor W.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="aff012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Passamonti</surname>
                    <given-names>Luca</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="aff013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rowe</surname>
                    <given-names>James B.</given-names>
                  </name>
                  <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Physical Therapy, The Stanley Steyer School of Health Professions, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Division of Clinical Pharmacology, Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>Department of Psychology, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff011">
                <label>11</label>
                <addr-line>Wellcome–MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff012">
                <label>12</label>
                <addr-line>Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United Kingdom</addr-line>
              </aff>
              <aff id="aff013">
                <label>13</label>
                <addr-line>Istituto di Bioimmagini e Fisiologia Molecolare, Consiglio Nazionale delle Ricerche, Milan, Italy</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Ahn</surname>
                    <given-names>Woo-Young</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Seoul National University, REPUBLIC OF KOREA</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>frankhezemans@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>9</day>
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <volume>18</volume>
              <issue>5</issue>
              <elocation-id>e1010079</elocation-id>
              <history>
                <date date-type="received">
                  <day>5</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 Hezemans et al</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Hezemans et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pcbi.1010079.pdf"/>
              <abstract>
                <p>Apathy is a debilitating feature of many neuropsychiatric diseases, that is typically described as a reduction of goal-directed behaviour. Despite its prevalence and prognostic importance, the mechanisms underlying apathy remain controversial. Degeneration of the locus coeruleus-noradrenaline system is known to contribute to motivational deficits, including apathy. In healthy people, noradrenaline has been implicated in signalling the uncertainty of expectations about the environment. We proposed that noradrenergic deficits contribute to apathy by modulating the relative weighting of prior beliefs about action outcomes. We tested this hypothesis in the clinical context of Parkinson’s disease, given its associations with apathy and noradrenergic dysfunction. Participants with mild-to-moderate Parkinson’s disease (<italic toggle="yes">N</italic> = 17) completed a randomised double-blind, placebo-controlled, crossover study with 40 mg of the noradrenaline reuptake inhibitor atomoxetine. Prior weighting was inferred from psychophysical analysis of performance in an effort-based visuomotor task, and was confirmed as negatively correlated with apathy. Locus coeruleus integrity was assessed <italic toggle="yes">in vivo</italic> using magnetisation transfer imaging at ultra-high field 7T. The effect of atomoxetine depended on locus coeruleus integrity: participants with a more degenerate locus coeruleus showed a greater increase in prior weighting on atomoxetine <italic toggle="yes">versus</italic> placebo. The results indicate a contribution of the noradrenergic system to apathy and potential benefit from noradrenergic treatment of people with Parkinson’s disease, subject to stratification according to locus coeruleus integrity. More broadly, these results reconcile emerging predictive processing accounts of the role of noradrenaline in goal-directed behaviour with the clinical symptom of apathy and its potential pharmacological treatment.</p>
              </abstract>
              <abstract abstract-type="summary">
                <title>Author summary</title>
                <p>Apathy is a common and harmful consequence of many neuropsychiatric diseases. Its underlying causes are not fully understood, which prevents the development of new treatments. We approach the problem in a new way, modelling human behaviour in terms of the continuously updated interaction between sensory information and brain-based predictions or ‘priors’ about the consequences of our actions. We have previously shown that apathy is related to a loss of precision of these ‘priors’. We proposed that the precision is controlled by noradrenaline (like adrenaline, but made in the brain). We tested whether the noradrenaline-enhancing drug called atomoxetine can restore the priors’ precision in apathetic people. We enrolled participants with Parkinson’s disease, which is associated with both apathy and noradrenaline loss. We used ultra-high field MRI to measure individual differences in the integrity of specialist region called the locus coeruleus–the brain’s source of noradrenaline. We found that the effect of treatment with atomoxetine on prior precision depended on locus coeruleus integrity: Participants with a degenerated locus coeruleus had a more positive change in prior precision. Our results highlight how individual differences in neuroanatomy can predict the potential benefit of noradrenaline treatments in people suffering from apathy.</p>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100019544</institution-id>
                      <institution>Cambridge Centre for Parkinson-Plus</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>RG95450</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>Parkinson's UK research grant</institution>
                  </funding-source>
                  <award-id>K-1702</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution>James S. McDonnell Foundation 21st Century Science Initiative</institution>
                  </funding-source>
                  <award-id>Scholar Award in Understanding Human Cognition</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100004440</institution-id>
                      <institution>Wellcome Trust</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>220258</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award005">
                  <funding-source>
                    <institution>Cambridge Trust Vice-Chancellor's Award Award for Medical Sciences</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0092-3289</contrib-id>
                    <name>
                      <surname>Hezemans</surname>
                      <given-names>Frank H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award006">
                  <funding-source>
                    <institution>Fitzwilliam College scholarship</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0092-3289</contrib-id>
                    <name>
                      <surname>Hezemans</surname>
                      <given-names>Frank H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award007">
                  <funding-source>
                    <institution>National Institute for Health and Care Research</institution>
                  </funding-source>
                  <award-id>Academic Clinical Fellowship (ACF-2019-14-013)</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4652-7727</contrib-id>
                    <name>
                      <surname>Wolpe</surname>
                      <given-names>Noham</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award008">
                  <funding-source>
                    <institution>Australian National Health and Medical Research Council</institution>
                  </funding-source>
                  <award-id>Neil Hamilton Fairley Fellowship (GNT1091310)</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5698-6364</contrib-id>
                    <name>
                      <surname>O’Callaghan</surname>
                      <given-names>Claire</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award009">
                  <funding-source>
                    <institution>Holt Fellowship</institution>
                  </funding-source>
                  <award-id>RG86564</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0813-0670</contrib-id>
                    <name>
                      <surname>Murley</surname>
                      <given-names>Alexander G.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award010">
                  <funding-source>
                    <institution>Association of British Neurologists, Patrick Berthoud Charitable Trust</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3813-0882</contrib-id>
                    <name>
                      <surname>Holland</surname>
                      <given-names>Negin</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award011">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000286</institution-id>
                      <institution>British Academy</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>PF160048</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3178-6363</contrib-id>
                    <name>
                      <surname>Tsvetanov</surname>
                      <given-names>Kamen A.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award012">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000627</institution-id>
                      <institution>Guarantors of Brain</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>101149</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3178-6363</contrib-id>
                    <name>
                      <surname>Tsvetanov</surname>
                      <given-names>Kamen A.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award013">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000690</institution-id>
                      <institution>Research Councils UK</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/R007446/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Williams-Gray</surname>
                      <given-names>Caroline H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award014">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000690</institution-id>
                      <institution>Research Councils UK</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>SUAG/051 G101400</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award015">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100000690</institution-id>
                      <institution>Research Councils UK</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/P01271X/1</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Rowe</surname>
                      <given-names>James B.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>The study was primarily supported by the Cambridge Centre for Parkinson-Plus to JBR, RAB and CWG (RG95450), with additional support from a Parkinson's UK research grant to JBR and CO (K-1702; <ext-link xlink:href="https://www.parkinsons.org.uk/" ext-link-type="uri">https://www.parkinsons.org.uk/</ext-link>), a James S. McDonnell Foundation 21st Century Science Initiative Scholar Award in Understanding Human Cognition, to JBR (<ext-link xlink:href="https://www.jsmf.org/" ext-link-type="uri">https://www.jsmf.org/</ext-link>) and an Investigator Award from the Wellcome Trust to JBR (220258; <ext-link xlink:href="https://wellcome.org/" ext-link-type="uri">https://wellcome.org/</ext-link>). FHH was supported by a Cambridge Trust Vice-Chancellor's Award and Fitzwilliam College scholarship (<ext-link xlink:href="https://www.cambridgetrust.org/" ext-link-type="uri">https://www.cambridgetrust.org/</ext-link>). NW was supported by an Academic Clinical Fellowship (ACF-2019-14-013) from the National Institute for Health and Care Research (<ext-link xlink:href="https://www.nihr.ac.uk/" ext-link-type="uri">https://www.nihr.ac.uk/</ext-link>). CO was supported by a Neil Hamilton Fairley Fellowship from the Australian National Health and Medical Research Council (GNT1091310; <ext-link xlink:href="https://www.nhmrc.gov.au/" ext-link-type="uri">https://www.nhmrc.gov.au/</ext-link>). AGM was supported by the Holt Fellowship (RG86564). NH was supported by the Association of British Neurologists, Patrick Berthoud Charitable Trust (RG99368; <ext-link xlink:href="https://www.theabn.org/" ext-link-type="uri">https://www.theabn.org/</ext-link>). KAT was supported by the British Academy (PF160048; <ext-link xlink:href="https://www.thebritishacademy.ac.uk/" ext-link-type="uri">https://www.thebritishacademy.ac.uk/</ext-link>) and the Guarantors of Brain (101149; <ext-link xlink:href="https://guarantorsofbrain.org/" ext-link-type="uri">https://guarantorsofbrain.org/</ext-link>). CHW-G was supported by an RCUK/UKRI Research Innovation Fellowship awarded by the UK Medical Research Council (MR/R007446/1; <ext-link xlink:href="https://mrc.ukri.org/" ext-link-type="uri">https://mrc.ukri.org/</ext-link>). JBR was supported by intramural funding (SUAG/051 G101400) and a research grant (MR/P01271X/1) from the UK Medical Research Council (<ext-link xlink:href="https://mrc.ukri.org/" ext-link-type="uri">https://mrc.ukri.org/</ext-link>). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; <ext-link xlink:href="https://cambridgebrc.nihr.ac.uk/" ext-link-type="uri">https://cambridgebrc.nihr.ac.uk/</ext-link>). For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="5"/>
                <table-count count="1"/>
                <page-count count="30"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>PLOS Publication Stage</meta-name>
                  <meta-value>vor-update-to-uncorrected-proof</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>Publication Update</meta-name>
                  <meta-value>2022-05-19</meta-value>
                </custom-meta>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>Code and de-identified behavioural data and summary imaging metrics to reproduce statistical analyses, computational modelling and manuscript figures are freely available through the Open Science Framework: <ext-link xlink:href="https://osf.io/mry4f/" ext-link-type="uri">https://osf.io/mry4f/</ext-link>.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>Code and de-identified behavioural data and summary imaging metrics to reproduce statistical analyses, computational modelling and manuscript figures are freely available through the Open Science Framework: <ext-link xlink:href="https://osf.io/mry4f/" ext-link-type="uri">https://osf.io/mry4f/</ext-link>.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec001">
              <title>Introduction</title>
              <p>Apathy is a common and debilitating feature of many neuropsychiatric diseases, including Parkinson’s disease [<xref rid="pcbi.1010079.ref001" ref-type="bibr">1</xref>–<xref rid="pcbi.1010079.ref003" ref-type="bibr">3</xref>], and it occurs to varying degrees in the healthy population [<xref rid="pcbi.1010079.ref004" ref-type="bibr">4</xref>,<xref rid="pcbi.1010079.ref005" ref-type="bibr">5</xref>]. The reduction of goal-directed behaviour is typically attributed to dopamine-dependent loss of motivation [<xref rid="pcbi.1010079.ref006" ref-type="bibr">6</xref>,<xref rid="pcbi.1010079.ref007" ref-type="bibr">7</xref>], but it remains poorly understood. New treatments targeting apathy require mechanistic neurocognitive and psychopharmacological models [<xref rid="pcbi.1010079.ref008" ref-type="bibr">8</xref>].</p>
              <p>Many psychopharmacological studies of apathy and Parkinson’s disease focus on dopamine [<xref rid="pcbi.1010079.ref009" ref-type="bibr">9</xref>], relating the striatal dopamine deficit in Parkinson’s disease [<xref rid="pcbi.1010079.ref010" ref-type="bibr">10</xref>] to the role of dopamine in reinforcement learning, along with value- and effort-based decision-making [<xref rid="pcbi.1010079.ref011" ref-type="bibr">11</xref>,<xref rid="pcbi.1010079.ref012" ref-type="bibr">12</xref>]. Apathetic individuals with Parkinson’s disease exert less effort for a given reward, and acute withdrawal studies demonstrate a dopaminergic modulation of this effect [<xref rid="pcbi.1010079.ref013" ref-type="bibr">13</xref>–<xref rid="pcbi.1010079.ref015" ref-type="bibr">15</xref>].</p>
              <p>However, the dopaminergic model of apathy has limitations. First, apathy is positively correlated with impulsivity, which has been attributed to hyper-dopaminergic states [<xref rid="pcbi.1010079.ref005" ref-type="bibr">5</xref>,<xref rid="pcbi.1010079.ref016" ref-type="bibr">16</xref>–<xref rid="pcbi.1010079.ref019" ref-type="bibr">19</xref>]. Second, apathy is common in Parkinson’s disease patients despite dopamine replacement therapy, and may follow deep brain stimulation therapy [<xref rid="pcbi.1010079.ref020" ref-type="bibr">20</xref>]. There is no clear relationship between apathy severity and dopaminergic medication dose [<xref rid="pcbi.1010079.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1010079.ref019" ref-type="bibr">19</xref>]. Third, evidence from animal models implicates non-dopaminergic neurotransmitter systems–in particular, noradrenaline–in motivation and effort-based decision-making [<xref rid="pcbi.1010079.ref021" ref-type="bibr">21</xref>–<xref rid="pcbi.1010079.ref023" ref-type="bibr">23</xref>].</p>
              <p>The locus coeruleus is the principal source of noradrenaline in the brain [<xref rid="pcbi.1010079.ref024" ref-type="bibr">24</xref>,<xref rid="pcbi.1010079.ref025" ref-type="bibr">25</xref>]. In Parkinson’s disease, it undergoes early and severe pathological changes [<xref rid="pcbi.1010079.ref026" ref-type="bibr">26</xref>–<xref rid="pcbi.1010079.ref028" ref-type="bibr">28</xref>], and this has been associated with certain cognitive and motivational problems that are insensitive to dopamine medication [<xref rid="pcbi.1010079.ref008" ref-type="bibr">8</xref>,<xref rid="pcbi.1010079.ref029" ref-type="bibr">29</xref>–<xref rid="pcbi.1010079.ref032" ref-type="bibr">32</xref>].</p>
              <p>A growing body of work suggests that noradrenaline signals the uncertainty of an individual’s internal model of their environment. For example, phasic bursts of noradrenaline follow salient sensory inputs and promote behavioural adaptation [<xref rid="pcbi.1010079.ref033" ref-type="bibr">33</xref>,<xref rid="pcbi.1010079.ref034" ref-type="bibr">34</xref>], while tonic release of noradrenaline correlates with higher-order contextual features such as the volatility of the environment or utility of a task, controlling the gain and selectivity of neural networks [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1010079.ref036" ref-type="bibr">36</xref>]. Evidence from pharmacological manipulations and from pupillometry data (a surrogate marker of locus coeruleus activity [<xref rid="pcbi.1010079.ref037" ref-type="bibr">37</xref>]) suggests that noradrenergic signalling indicates the extent to which sensory input is used to update existing beliefs and uncertainty of internal models [<xref rid="pcbi.1010079.ref038" ref-type="bibr">38</xref>–<xref rid="pcbi.1010079.ref042" ref-type="bibr">42</xref>]. The ability to flexibly update internal models permits adaptive engagement with the environment–supporting goal-directed, motivated behaviour. Disruption in this ability is directly relevant to apathy.</p>
              <p>We previously proposed that apathy is a result of the dependence of motivated behaviour on the relative precision of prior beliefs about action outcomes [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>]. With predictive processing, the brain optimises a probabilistic model of its environment, minimising ‘surprise’ or prediction error via action and perception [<xref rid="pcbi.1010079.ref044" ref-type="bibr">44</xref>,<xref rid="pcbi.1010079.ref045" ref-type="bibr">45</xref>]. The balance between active and passive (sensory) inference depends on the relative precision of prior beliefs and sensory evidence. When priors are held with high precision, they will be maintained despite conflicting (but imprecise) sensory evidence, and induce action to minimise the prediction error. That is, sensory evidence is changed by action to fulfil prior beliefs held with high precision [<xref rid="pcbi.1010079.ref046" ref-type="bibr">46</xref>–<xref rid="pcbi.1010079.ref048" ref-type="bibr">48</xref>]. If precision on the priors is not sufficiently high, passive (sensory) inference occurs by adjusting perceptual priors, and no goal-directed action is necessary.</p>
              <p>The implication for apathy is that the loss of prior precision relative to sensory evidence would lead to a failure of action, because imprecise priors that conflict with sensory evidence are passively revised rather than actively fulfilled [<xref rid="pcbi.1010079.ref047" ref-type="bibr">47</xref>,<xref rid="pcbi.1010079.ref049" ref-type="bibr">49</xref>]. There would be an apparent ‘acceptance’ of the state of the world, even if discordant with goals. In support of this hypothesis, trait apathy is negatively correlated with prior precision of outcomes: more apathetic individuals have less precise prior beliefs [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>]. Crucially, precision weighting has been associated with neurotransmitter systems that include noradrenaline [<xref rid="pcbi.1010079.ref050" ref-type="bibr">50</xref>–<xref rid="pcbi.1010079.ref053" ref-type="bibr">53</xref>].</p>
              <p>This study tested the noradrenergic contributions to apathy in Parkinson’s disease. We hypothesised that apathy is associated with reduced weighting of prior beliefs about action outcomes, and that this prior weighting is modulated by noradrenaline. We predicted baseline dependency of drug effects, such that the behavioural effect of a noradrenergic intervention depends on structural integrity of the locus coeruleus, in line with the inverted U-shaped dose-response curve of noradrenaline and other catecholamines [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1010079.ref054" ref-type="bibr">54</xref>–<xref rid="pcbi.1010079.ref056" ref-type="bibr">56</xref>]. We tested this hypothesis in Parkinson’s disease using an effortful goal-directed visuomotor task in combination with (i) modulation of noradrenaline using atomoxetine (a noradrenergic reuptake inhibitor) and (ii) measurement of structural integrity of the locus coeruleus via ultra-high field neuromelanin-sensitive magnetic resonance imaging. In view of the potential contribution of dopamine to apathy, control analyses included the levodopa equivalent daily dose and measurement of the substantia nigra contrast as covariates.</p>
            </sec>
            <sec sec-type="results" id="sec002">
              <title>Results</title>
              <p>Participants with mild-to-moderate idiopathic Parkinson’s disease (<italic toggle="yes">N</italic> = 17) completed a visuomotor task that involved effortful, goal-directed behaviour (<xref rid="pcbi.1010079.g001" ref-type="fig">Fig 1A</xref>). Their demographic and clinical details are outlined in <xref rid="pcbi.1010079.t001" ref-type="table">Table 1</xref>. They completed this task twice in a double-blind, placebo-controlled, randomised within-subjects crossover design, receiving the selective noradrenaline reuptake inhibitor atomoxetine (40 mg oral dose) or placebo. A healthy control group (<italic toggle="yes">N</italic> = 20; age-, sex- and education-matched to the Parkinson’s disease group) undertook the task once, without the atomoxetine manipulation, to provide normative data. In view of baseline dependency of drug effects and the anticipated use of restorative pharmacology in patients but not healthy adults, the placebo-controlled drug intervention was restricted to those with Parkinson’s disease. All participants underwent 7T MR imaging of the locus coeruleus using a magnetisation transfer weighted sequence in a baseline session, with atlas-based localisation of the locus coeruleus and contrast quantification [<xref rid="pcbi.1010079.ref057" ref-type="bibr">57</xref>]. The participants with Parkinson’s disease were on their regular anti-parkinsonian medication throughout the study. <xref rid="pcbi.1010079.t001" ref-type="table">Table 1</xref> provides an overview of the participant demographics; further details about the study design and clinical characteristics of the Parkinson’s disease group are provided in the Materials and Methods and <xref rid="pcbi.1010079.s006" ref-type="supplementary-material">S1 Text</xref>.</p>
              <fig position="float" id="pcbi.1010079.g001">
                <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Visuomotor task and Bayesian modelling approach.</title>
                  <p><bold>A)</bold> Participants performed a sustained finger press to trigger a ballistic ball trajectory, aiming it at a target. For the majority of trials, an animation of the ball trajectory was shown, and participants sought to minimise their performance error–the distance of the final ball position from the target (top row). For the remaining trials, the ball trajectory was hidden and participants were asked to estimate where the ball would have finished. Participants were given 12 evenly spaced response options, one of which was pseudorandomly selected to be centred on the true final ball position (i.e., the veridical response option). The difference between the chosen and veridical response option constitutes the estimation error (bottom row). The pointing finger image was adapted from the Wikimedia Commons, available at <ext-link xlink:href="https://commons.wikimedia.org/wiki/File:Index_finger_down.JPG" ext-link-type="uri">https://commons.wikimedia.org/wiki/File:Index_finger_down.JPG</ext-link> under a CC BY-SA 3.0 license (<ext-link xlink:href="https://creativecommons.org/licenses/by-sa/3.0/" ext-link-type="uri">https://creativecommons.org/licenses/by-sa/3.0/</ext-link>). <bold>B)</bold> Estimates of performance were modelled as a precision-weighted combination of a prior, centred on the target, and trial-wise sensory evidence, centred on the true final ball position. The relationship between estimation errors and performance errors is indicative of prior weighting–the precision of the prior relative to sensory evidence. <bold>C)</bold> Simulation demonstrating that prior weighting corresponds to the slope of the linear relationship between performance error and estimation error. For a given performance error and setting of prior weighting, the bold line represents the median predicted estimation error, and the increasingly transparent shaded areas represent the 25% and 50% quantile intervals of the predicted estimation error, respectively.</p>
                </caption>
                <graphic xlink:href="pcbi.1010079.g001" position="float"/>
              </fig>
              <table-wrap position="float" id="pcbi.1010079.t001">
                <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Demographics and clinical characteristics of participants.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pcbi.1010079.t001" id="pcbi.1010079.t001g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" colspan="2" rowspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Parkinson’s disease</th>
                        <th align="center" rowspan="1" colspan="1">Controls</th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">BF</italic>
                        </th>
                        <th align="center" rowspan="1" colspan="1">
                          <italic toggle="yes">p</italic>
                        </th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Age (years)</td>
                        <td align="center" rowspan="1" colspan="1">66.94 (7.29)</td>
                        <td align="center" rowspan="1" colspan="1">65.40 (5.97)</td>
                        <td align="center" rowspan="1" colspan="1">0.39</td>
                        <td align="center" rowspan="1" colspan="1">.492</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Education (years)</td>
                        <td align="center" rowspan="1" colspan="1">14.24 (2.17)</td>
                        <td align="center" rowspan="1" colspan="1">14.30 (3.29)</td>
                        <td align="center" rowspan="1" colspan="1">0.32</td>
                        <td align="center" rowspan="1" colspan="1">.943</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Male / Female</td>
                        <td align="center" rowspan="1" colspan="1">15 / 2</td>
                        <td align="center" rowspan="1" colspan="1">12 / 8</td>
                        <td align="center" rowspan="1" colspan="1">2.04</td>
                        <td align="center" rowspan="1" colspan="1">.120</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Apathy Scale (max. 42)</td>
                        <td align="center" rowspan="1" colspan="1">12.68 (5.77)</td>
                        <td align="center" rowspan="1" colspan="1">10.58 (5.09)</td>
                        <td align="center" rowspan="1" colspan="1">0.58</td>
                        <td align="center" rowspan="1" colspan="1">.212</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">MMSE (max. 30)</td>
                        <td align="center" rowspan="1" colspan="1">29.47 (0.72)</td>
                        <td align="center" rowspan="1" colspan="1">29.80 (0.52)</td>
                        <td align="center" rowspan="1" colspan="1">0.87</td>
                        <td align="center" rowspan="1" colspan="1">.127</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">MoCA (max. 30)</td>
                        <td align="center" rowspan="1" colspan="1">28.00 (1.84)</td>
                        <td align="center" rowspan="1" colspan="1">28.35 (1.50)</td>
                        <td align="center" rowspan="1" colspan="1">0.37</td>
                        <td align="center" rowspan="1" colspan="1">.535</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="6" colspan="1">ACE-R</td>
                        <td align="left" rowspan="1" colspan="1">Total Score (max. 100)</td>
                        <td align="center" rowspan="1" colspan="1">95.12 (3.72)</td>
                        <td align="center" rowspan="1" colspan="1">97.55 (3.46)</td>
                        <td align="center" rowspan="1" colspan="1">1.60</td>
                        <td align="center" rowspan="1" colspan="1">.049</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Attention &amp; Orientation (max. 18)</td>
                        <td align="center" rowspan="1" colspan="1">17.82 (0.39)</td>
                        <td align="center" rowspan="1" colspan="1">17.95 (0.22)</td>
                        <td align="center" rowspan="1" colspan="1">0.57</td>
                        <td align="center" rowspan="1" colspan="1">.251</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Memory (max. 26)</td>
                        <td align="center" rowspan="1" colspan="1">23.76 (2.05)</td>
                        <td align="center" rowspan="1" colspan="1">25.05 (1.19)</td>
                        <td align="center" rowspan="1" colspan="1">2.68</td>
                        <td align="center" rowspan="1" colspan="1">.031</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fluency (max. 14)</td>
                        <td align="center" rowspan="1" colspan="1">12.18 (1.94)</td>
                        <td align="center" rowspan="1" colspan="1">12.85 (1.76)</td>
                        <td align="center" rowspan="1" colspan="1">0.51</td>
                        <td align="center" rowspan="1" colspan="1">.280</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Language (max. 26)</td>
                        <td align="center" rowspan="1" colspan="1">25.82 (0.53)</td>
                        <td align="center" rowspan="1" colspan="1">25.90 (0.45)</td>
                        <td align="center" rowspan="1" colspan="1">0.35</td>
                        <td align="center" rowspan="1" colspan="1">.641</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Visuospatial (max. 16)</td>
                        <td align="center" rowspan="1" colspan="1">15.65 (0.49)</td>
                        <td align="center" rowspan="1" colspan="1">15.80 (0.70)</td>
                        <td align="center" rowspan="1" colspan="1">0.40</td>
                        <td align="center" rowspan="1" colspan="1">.441</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="5" colspan="1">MDS-UPDRS</td>
                        <td align="left" rowspan="1" colspan="1">I: Nonmotor experiences (max. 52)</td>
                        <td align="center" rowspan="1" colspan="1">8.41 (3.87)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">II: Motor experiences (max. 52)</td>
                        <td align="center" rowspan="1" colspan="1">12.76 (4.49)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">III: Motor Examination (max. 132)</td>
                        <td align="center" rowspan="1" colspan="1">27.94 (12.05)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IV: Motor Complications (max. 24)</td>
                        <td align="center" rowspan="1" colspan="1">0.35 (0.79)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Total Score (max. 260)</td>
                        <td align="center" rowspan="1" colspan="1">49.53 (17.55)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Hoehn and Yahr stage (max. 5)</td>
                        <td align="center" rowspan="1" colspan="1">2.24 (0.44)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Disease duration (years)</td>
                        <td align="center" rowspan="1" colspan="1">4.15 (1.72)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="2" rowspan="1">Levodopa equivalent daily dose (mg/day)</td>
                        <td align="center" rowspan="1" colspan="1">659.94 (514.90)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p><italic toggle="yes">Note</italic>. Data are presented as mean (SD). Group comparisons were performed with independent samples t-tests or contingency tables as appropriate. The stated <italic toggle="yes">p</italic>-values are uncorrected; none survived <italic toggle="yes">p</italic> &lt; .05 after correction for multiple comparisons. The participants with Parkinson’s disease were tested on their regular medications. Levodopa equivalent daily dose was calculated based on Tomlinson et al. [<xref rid="pcbi.1010079.ref058" ref-type="bibr">58</xref>]. Apathy Scale refers to the total score for the self-rated version of the Starkstein et al. [<xref rid="pcbi.1010079.ref059" ref-type="bibr">59</xref>] questionnaire. Abbreviations: BF, Bayes Factor for the alternative hypothesis over the null hypothesis, where &gt; 3 would indicate positive evidence in favour of a group difference; MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; ACE-R, Addenbrooke’s Cognitive Examination—Revised; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="sec003">
                <title>Visuomotor task</title>
                <p>The visuomotor task involved effortful, goal-directed behaviour, and was designed to estimate prior weighting, i.e. the relative precision of prior beliefs and sensory evidence in the perception of action outcomes. Using their dominant hand, participants pressed a force sensor to trigger a ballistic ball movement on the screen, aiming for the ball to stop on a target. The force exerted on the sensor (relative to the participant’s maximum force, measured separately) determined the initial velocity of the ball. Since the deceleration of the ball was constant, the force response (i.e., initial velocity) directly determined the ball’s final position. The difference between the ball’s final position and the target constituted the performance error. For 40 out of the total 120 trials, the ball’s trajectory was not shown, and participants were asked to estimate where the ball would have stopped, indicating their response on a grid of 12 response options (<xref rid="pcbi.1010079.g001" ref-type="fig">Fig 1A</xref>; see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details). The difference between the participant’s selected response option and the response option that was centred on the true final ball position constituted the estimation error. The linear relationship between estimation errors and performance errors was used to infer prior weighting (<xref rid="pcbi.1010079.g001" ref-type="fig">Fig 1B and 1C</xref>; see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details).</p>
                <p>We first tested for differences in basic task performance between drug conditions within the Parkinson’s disease group (atomoxetine vs. placebo). We also tested the effect of group (Parkinson’s disease on placebo vs. controls) noting the multiple differences between these groups, including the presence of Parkinson’s disease, the placebo effect, and repetition effects.</p>
                <p>We examined to what extent the force exerted on the force sensor matched the force required to stop the ball on target (force error; see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details). Among the Parkinson’s disease group there was no significant effect of atomoxetine on either the median force error (Δ drug: M = 0.64%, SD = 1.84%; <italic toggle="yes">t</italic><sub>(16)</sub> = 1.44, <italic toggle="yes">p</italic> = .168; <italic toggle="yes">BF</italic> = 0.60) or the interquartile range of force error (Δ drug: M = -0.09%, SD = 2.59%; <italic toggle="yes">t</italic><sub>(16)</sub> = -0.14, <italic toggle="yes">p</italic> = .892; <italic toggle="yes">BF</italic> = 0.25). We found no significant differences between the Parkinson’s disease and control groups, in terms of the median force error (controls: M = 0.69%, SD = 3.21%; PD placebo: M = -0.48%, SD = 2.78%; <italic toggle="yes">t</italic><sub>(34.98)</sub> = 1.19, <italic toggle="yes">p</italic> = .242; <italic toggle="yes">BF</italic> = 0.55) and the interquartile range of force error (controls: M = 9.92%, SD = 3.73%; PD placebo: M = 9.19%, SD = 3.47%; <italic toggle="yes">t</italic><sub>(34.69)</sub> = 0.62, <italic toggle="yes">p</italic> = .540; <italic toggle="yes">BF</italic> = 0.37).</p>
              </sec>
              <sec id="sec004">
                <title>Prior weighting and apathy</title>
                <p>We next examined participants’ estimates of their own performance, to infer the relative weight afforded to prior beliefs in the perception of action outcomes. Following Bayes’ rule, participants are assumed to combine their prior belief, centred on the target, with trial-wise sensory evidence, centred on the (hidden) true final ball position, to estimate the ball’s final position (<xref rid="pcbi.1010079.g001" ref-type="fig">Fig 1B</xref>). Assuming that the prior and sensory evidence are represented as Gaussian distributions with unknown variances <inline-formula id="pcbi.1010079.e001"><alternatives><graphic xlink:href="pcbi.1010079.e001.jpg" id="pcbi.1010079.e001g" position="anchor"/><mml:math id="M1" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1010079.e002"><alternatives><graphic xlink:href="pcbi.1010079.e002.jpg" id="pcbi.1010079.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, the posterior estimate for a given trial <inline-formula id="pcbi.1010079.e003"><alternatives><graphic xlink:href="pcbi.1010079.e003.jpg" id="pcbi.1010079.e003g" position="anchor"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mi>n</mml:mi><mml:mspace width="0.25em"/><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> is a precision-weighted sum of the target position <inline-formula id="pcbi.1010079.e004"><alternatives><graphic xlink:href="pcbi.1010079.e004.jpg" id="pcbi.1010079.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and the true final ball position <inline-formula id="pcbi.1010079.e005"><alternatives><graphic xlink:href="pcbi.1010079.e005.jpg" id="pcbi.1010079.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>:
<disp-formula id="pcbi.1010079.e006"><alternatives><graphic xlink:href="pcbi.1010079.e006.jpg" id="pcbi.1010079.e006g" position="anchor"/><mml:math id="M6" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives><label>(1)</label></disp-formula>
where the prior weighting term <italic toggle="yes">w</italic><sub>prior</sub> is given by:
<disp-formula id="pcbi.1010079.e007"><alternatives><graphic xlink:href="pcbi.1010079.e007.jpg" id="pcbi.1010079.e007g" position="anchor"/><mml:math id="M7" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:math></alternatives><label>(2)</label></disp-formula></p>
                <p>By subtracting the true final ball position from both sides of <xref rid="pcbi.1010079.e006" ref-type="disp-formula">Eq 1</xref>, we can express estimation errors as a function of performance errors:
<disp-formula id="pcbi.1010079.e008"><alternatives><graphic xlink:href="pcbi.1010079.e008.jpg" id="pcbi.1010079.e008g" position="anchor"/><mml:math id="M8" display="block" overflow="scroll"><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>∙</mml:mo><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder></mml:math></alternatives><label>(3)</label></disp-formula></p>
                <p>Thus, the regression coefficient of estimation errors by performance errors corresponds to the negative of the prior weighting term [<xref rid="pcbi.1010079.ref060" ref-type="bibr">60</xref>]. This is illustrated in <xref rid="pcbi.1010079.g001" ref-type="fig">Fig 1C</xref> using simulated data: higher values of prior weighting yield estimates that are strongly drawn towards the target and away from the true final ball position. When prior weighting approaches 1, the estimation errors overwhelm the performance errors, reflecting a disregard for sensory evidence of poor performance. When prior weighting approaches 0, the estimates are in line with the true performance. We used a linear mixed effects model to estimate the relationship between estimation error and performance error, allowing the slope (i.e., negative prior weighting) to vary for each testing session for each participant. Note that this model was only fit to the subset of trials where the ball’s visual trajectory was not shown (i.e., estimation trials, see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details). Thus, the participants could not have used visual information to infer the ball’s final position.</p>
                <p>We confirmed that prior weighting was negatively associated with apathy, as measured by the Apathy Scale (AS)[<xref rid="pcbi.1010079.ref059" ref-type="bibr">59</xref>]. Prior weighting estimates from the Parkinson’s disease group on placebo and the control group were regressed against apathy, group (Parkinson’s disease vs. controls) and their interaction. To avoid confounding individual differences in prior weighting with basic task performance, we included the interquartile range of performance error as a covariate of no interest. We found a negative association between prior weighting and apathy, controlling for effects of group and performance error variability (<xref rid="pcbi.1010079.g002" ref-type="fig">Fig 2B</xref>; β = -0.35, SE = 0.15, <italic toggle="yes">t</italic><sub>(32)</sub> = -2.31, <italic toggle="yes">p</italic> = .028; <italic toggle="yes">BF</italic> = 2.30). This corroborates the negative relationship between prior weighting and trait apathy in healthy young adults [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>]: more apathetic individuals show reduced prior weighting (<xref rid="pcbi.1010079.s001" ref-type="supplementary-material">S1 Fig</xref>). There was no group-wise difference in prior weighting between controls and patients on placebo (<xref rid="pcbi.1010079.g002" ref-type="fig">Fig 2A</xref>; controls: M = 0.48, SD = 0.21; PD placebo: M = 0.45, SD = 0.26; β = 0.03, SE = 0.15, <italic toggle="yes">t</italic><sub>(32)</sub> = 0.20, <italic toggle="yes">p</italic> = .845; <italic toggle="yes">BF</italic> = 0.41), nor evidence for a group × apathy interaction effect (β = 0.17, SE = 0.15, <italic toggle="yes">t</italic><sub>(32)</sub> = 1.08, <italic toggle="yes">p</italic> = .287; <italic toggle="yes">BF</italic> = 0.60).</p>
                <fig position="float" id="pcbi.1010079.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Prior weighting and apathy.</title>
                    <p><bold>A)</bold> Estimates of prior weighting, obtained through a linear mixed effects model of estimation errors against performance errors. For the Parkinson’s disease group, the grey lines indicate within-subject change in prior weighting from placebo to atomoxetine. Box-plot elements: centre line, median; box limits, first and third quartiles; whiskers, most extreme observations (all within 1.5 × interquartile range from the box limits). <bold>B)</bold> The relationship between apathy and prior weighting, adjusted for the effects of group and task performance variability (i.e., partial residuals). Note that observations with identical questionnaire scores were horizontally jittered to avoid overlaid dots.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1010079.g002" position="float"/>
                </fig>
              </sec>
              <sec id="sec005">
                <title>Prior weighting and noradrenaline</title>
                <p>Having established that prior weighting was associated with apathy, we tested whether atomoxetine affected prior weighting in the Parkinson’s disease group (<xref rid="pcbi.1010079.g003" ref-type="fig">Fig 3A</xref>). On average across the group, there was no difference in prior weighting between the atomoxetine and placebo sessions (<xref rid="pcbi.1010079.g002" ref-type="fig">Fig 2A</xref>; Δ drug: M = -8.50 × 10<sup>−4</sup>, SD = 0.27; <italic toggle="yes">t</italic><sub>(16)</sub> = -0.01, <italic toggle="yes">p</italic> = .990; <italic toggle="yes">BF</italic> = 0.25). However, the between-subject variance in prior weighting was reduced on atomoxetine relative to placebo (Pitman’s test of equality of variance for paired data: <italic toggle="yes">t</italic><sub>(15)</sub> = -2.24, <italic toggle="yes">p</italic> = .041; <italic toggle="yes">BF</italic> = 2.46), which suggests a baseline-dependent drug effect [<xref rid="pcbi.1010079.ref061" ref-type="bibr">61</xref>].</p>
                <fig position="float" id="pcbi.1010079.g003">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Baseline-dependent effects of noradrenaline on prior weighting.</title>
                    <p><bold>A)</bold> Schematic overview of the noradrenergic drug study. The first session involved 7T MRI of the locus coeruleus, to estimate the mean contrast-to-noise ratio (CNR). The second and third sessions formed a double-blind randomised placebo-controlled crossover study, with 40 mg of oral atomoxetine of placebo. Two hours after drug administration, participants performed the visuomotor task that was designed to estimate prior weighting. <bold>B)</bold> Study-specific independent locus coeruleus atlas (red) and reference region in the central pons (blue). Image reused from O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>] under a CC-BY 4.0 license (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>). <bold>C)</bold> Estimates of prior weighting for participants with Parkinson’s disease, plotted as a function of their locus coeruleus CNR and the drug condition. Within-subject change in prior weighting from placebo to atomoxetine is indicated by the grey arrows. <bold>D)</bold> The relationship between the drug-induced change in prior weighting (atomoxetine minus placebo) and locus coeruleus CNR.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1010079.g003" position="float"/>
                </fig>
                <p>We had predicted that the effect of atomoxetine depends on the structural integrity of the locus coeruleus, as indexed by its contrast to noise ratio (CNR; <xref rid="pcbi.1010079.g003" ref-type="fig">Fig 3B</xref>; see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details). To test this, we entered prior weighting as the dependent variable in a linear mixed effects model with drug condition, locus coeruleus CNR and their interaction as fixed effects, the interquartile range of performance error as a covariate of no interest, and a random effect of participants on the intercept. We observed evidence for an interaction effect between the drug condition and locus coeruleus CNR (<xref rid="pcbi.1010079.g003" ref-type="fig">Fig 3C</xref>; β = -0.38, SE = 0.14, <italic toggle="yes">F</italic><sub>(1, 15)</sub> = 7.91, <italic toggle="yes">p</italic> = .013; <italic toggle="yes">BF</italic> = 10.02), confirming that the effect of atomoxetine on prior weighting depended on locus coeruleus integrity. Specifically, the drug-induced change in prior weighting (atomoxetine vs. placebo) was negatively associated with locus coeruleus CNR, such that participants with lower locus coeruleus CNR tended to have a more positive change in prior weighting (<xref rid="pcbi.1010079.g003" ref-type="fig">Fig 3D</xref>; <italic toggle="yes">r</italic><sub>(15)</sub> = -0.59, <italic toggle="yes">p</italic> = .013; <italic toggle="yes">BF</italic> = 5.13). There were no main effects of the drug condition (β = -2.06 × 10<sup>−3</sup>, SE = 0.13, <italic toggle="yes">F</italic><sub>(1, 15)</sub> = 2.36 × 10<sup>−4</sup>, <italic toggle="yes">p</italic> = .988; <italic toggle="yes">BF</italic> = 0.29) or locus coeruleus CNR (β = -0.08, SE = 0.20, <italic toggle="yes">F</italic><sub>(1, 14)</sub> = 0.16, <italic toggle="yes">p</italic> = .695; <italic toggle="yes">BF</italic> = 0.43) on prior weighting.</p>
                <p>Supplementary analyses confirmed the robustness and specificity of the interaction effect between the drug condition and locus coeruleus CNR. First, using both frequentist and Bayesian model selection procedures, we found that this interaction persisted with additional covariates, including age, motor severity (UPDRS part III), levodopa equivalent daily dose, atomoxetine plasma level, and total intracranial volume (<xref rid="pcbi.1010079.s007" ref-type="supplementary-material">S2 Text</xref>). Second, we used a linear mixed effects model with CNR extracted from the substantia nigra, as a neuromelanin-rich control region [<xref rid="pcbi.1010079.ref063" ref-type="bibr">63</xref>]. There was no interaction effect between the drug condition and substantia nigra CNR on prior weighting (β = 0.16, SE = 0.16, <italic toggle="yes">F</italic><sub>(1, 15)</sub> = 0.94, <italic toggle="yes">p</italic> = .349; <italic toggle="yes">BF</italic> = 0.71). Third, the interaction with locus coeruleus CNR remained significant when using an alternative calculation for locus coeruleus contrast (contrast ratio to mean instead of SD; β = -0.41, SE = 0.13, <italic toggle="yes">F</italic><sub>(1, 15)</sub> = 9.79, <italic toggle="yes">p</italic> = .007; <italic toggle="yes">BF</italic> = 17.40), or when using the more conservative 25% probability mask to derive the locus coeruleus CNR (β = -0.42, SE = 0.13, <italic toggle="yes">F</italic><sub>(1, 15)</sub> = 10.25, <italic toggle="yes">p</italic> = .006; <italic toggle="yes">BF</italic> = 20.22). Fourth, re-fitting the original linear mixed effects model using a robust estimation method yielded qualitatively similar results (β = -0.38, SE = 0.15, <italic toggle="yes">t</italic><sub>(15)</sub> = -2.62, <italic toggle="yes">p</italic> = .019). Taken together, these findings underwrite the robustness and specificity of the drug × locus coeruleus CNR interaction.</p>
              </sec>
              <sec id="sec006">
                <title>Decomposition of noradrenergic effects on prior weighting</title>
                <p>As prior weighting represents the precision of the prior relative to the sensory evidence (<xref rid="pcbi.1010079.e007" ref-type="disp-formula">Eq 2</xref>), drug-induced changes in prior weighting could in principle be explained by changes in prior precision, sensory evidence precision, or both. We therefore fitted the Parkinson’s disease group data with a hierarchical Bayesian model that decomposed the drug effect on prior weighting into separate drug effects on the standard deviation of the prior and sensory evidence distributions (see <xref rid="sec009" ref-type="sec">Materials and Methods</xref> for details). The drug effect on the standard deviation of the prior was associated with the drug effect on prior weighting (<xref rid="pcbi.1010079.g004" ref-type="fig">Fig 4A</xref>; β = -0.66, SE = 0.19, <italic toggle="yes">t</italic><sub>(15)</sub> = -3.41, <italic toggle="yes">p</italic> = .004; <italic toggle="yes">BF</italic> = 10.43). This relationship was negative, such that those participants who had reduced prior weighting on atomoxetine, tended to have greater standard deviation of the prior (i.e., reduced prior precision). In contrast, there was no significant relationship between the drug effect on the standard deviation of sensory evidence and the drug effect on prior weighting (<xref rid="pcbi.1010079.g004" ref-type="fig">Fig 4B</xref>; β = -0.04, SE = 0.26, <italic toggle="yes">t</italic><sub>(15)</sub> = -0.15, <italic toggle="yes">p</italic> = .884; <italic toggle="yes">BF</italic> = 0.42).</p>
                <fig position="float" id="pcbi.1010079.g004">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Decomposition of noradrenergic effects on prior weighting.</title>
                    <p><bold>A-B)</bold> The relationship between the drug effect on prior weighting and Bayesian model estimates of the drug effect on the standard deviation of the prior distribution (A) and the standard deviation of the sensory evidence distribution (B). <bold>C)</bold> Schematic illustration of how the effect of atomoxetine on prior precision (red) determines the extent to which (posterior) estimates of performance (blue) are drawn towards the prior, for a given sensory evidence (black). Lighter shades of red represent less precise priors. The effect of prior precision on the posterior is illustrated with corresponding shades of blue.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1010079.g004" position="float"/>
                </fig>
                <p>To directly test whether the drug effect on prior weighting was more strongly associated with the drug effect on prior precision than the drug effect on sensory evidence precision, we performed a repeated-measures ANCOVA with the drug effect on prior weighting as a between-subjects covariate, the precision term (prior vs. sensory evidence) as the within-subjects factor, and the estimated drug effects on prior and sensory evidence precision as the dependent variable. We found evidence for the interaction between the precision term and the drug effect on prior weighting (<italic toggle="yes">F</italic><sub>(1, 15)</sub> = 8.34, <italic toggle="yes">p</italic> = .011; <italic toggle="yes">BF</italic> = 19.90), confirming that the relationships with the drug effects on prior and sensory evidence precision were significantly different from each other. We obtained similar results using a ‘plausible values’ analysis approach that accounts for uncertainty in the parameter estimates (<xref rid="pcbi.1010079.s008" ref-type="supplementary-material">S3 Text</xref>).</p>
                <p>Overall, these results suggest that the atomoxetine-induced change in prior weighting was primarily explained by changes in prior precision, and not by changes in sensory evidence precision (<xref rid="pcbi.1010079.g004" ref-type="fig">Fig 4C</xref>).</p>
              </sec>
              <sec id="sec007">
                <title>Apathy moderates noradrenergic effects on prior weighting</title>
                <p>Lastly, given the relationship between prior weighting and apathy (<xref rid="pcbi.1010079.g002" ref-type="fig">Fig 2A</xref>), we tested whether the effect of locus coeruleus integrity on the atomoxetine-induced change in prior weighting varied according to the observed apathy. We regressed the drug effect on prior weighting against locus coeruleus CNR, apathy, and their interaction. We observed a significant interaction effect between locus coeruleus CNR and apathy (β = -0.49, SE = 0.21, <italic toggle="yes">t</italic><sub>(13)</sub> = -2.34, <italic toggle="yes">p</italic> = .036; <italic toggle="yes">BF</italic> = 2.54), such that greater apathy was associated with a stronger (i.e. more negative) relationship between locus coeruleus CNR and atomoxetine’s effect on prior weighting (<xref rid="pcbi.1010079.g005" ref-type="fig">Fig 5A</xref>). Specifically, the Johnson-Neyman procedure [<xref rid="pcbi.1010079.ref064" ref-type="bibr">64</xref>] indicated that the regression coefficient of locus coeruleus CNR was significant when the Apathy Scale score was above 12 (<xref rid="pcbi.1010079.g005" ref-type="fig">Fig 5B</xref>). This significance threshold approximates the commonly used threshold for clinically significant apathy (14 or higher)[<xref rid="pcbi.1010079.ref059" ref-type="bibr">59</xref>]. These results suggest that the baseline-dependent noradrenergic effects on prior weighting is more likely to be observed among those participants who were apathetic. However, we note that the Bayes Factor of the interaction effect was “anecdotal”.</p>
                <fig position="float" id="pcbi.1010079.g005">
                  <object-id pub-id-type="doi">10.1371/journal.pcbi.1010079.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Baseline-dependent noradrenergic effects on prior weighting are moderated by apathy.</title>
                    <p><bold>A)</bold> The relationship between the drug effect on prior weighting and locus coeruleus CNR, plotted separately for above-average, average, and below-average scores on the Apathy Scale. Note that the Apathy Scale was treated as a continuous predictor in the reported statistical analyses, and is only discretised for visualisation purposes. <bold>B)</bold> Jonhson-Neyman interval plot, illustrating the range of scores on the Apathy Scale for which the regression coefficient of locus coeruleus CNR on the drug effect on prior weighting was statistically significant. The grey and blue shaded areas represent the 95% confidence interval for the predicted regression coefficient of locus coeruleus CNR, given the Apathy Scale score. The Apathy Scale scores (x-axis) were z-scored to facilitate interpretation of the regression coefficient (y-axis); the significance threshold of z = -0.02 (blue dashed line) corresponded to a score of 12.3.</p>
                  </caption>
                  <graphic xlink:href="pcbi.1010079.g005" position="float"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec008">
              <title>Discussion</title>
              <p>This study provides evidence that the locus coeruleus noradrenergic system regulates the balance between prior beliefs and sensory evidence for goal-directed behaviour, and its impairment contributes to apathy. Individual differences in the relative weight afforded to prior beliefs were negatively associated with apathy, such that more apathetic individuals had reduced prior weighting. Atomoxetine modulated this prior weighting in a baseline-dependent manner in people with Parkinson’s disease: people with reduced locus coeruleus integrity had a greater increase in prior weighting after atomoxetine, relative to a placebo. Using hierarchical Bayesian modelling, we demonstrated that this drug-induced change in prior weighting was primarily explained by changes in the precision of prior beliefs, and not by changes in the precision of sensory evidence. These results highlight the link between the noradrenergic locus coeruleus and the control of prior precision, during goal-directed behaviour. Given the early loss of noradrenergic cells in the locus coeruleus by Parkinson’s disease, this association suggests a contributory mechanism to apathy in Parkinson’s disease.</p>
              <p>We propose that increased weighting of prior beliefs following atomoxetine may help alleviate apathy. According to Bayesian models of brain function, actions require prior beliefs about their outcomes to be held with relatively high precision [<xref rid="pcbi.1010079.ref046" ref-type="bibr">46</xref>,<xref rid="pcbi.1010079.ref049" ref-type="bibr">49</xref>]. In Parkinson’s disease, the relative precision of predictive signals is compromised [<xref rid="pcbi.1010079.ref065" ref-type="bibr">65</xref>,<xref rid="pcbi.1010079.ref066" ref-type="bibr">66</xref>], which underlies the poverty of action selection and increased reliance on external cues for the initiation and maintenance of movement [<xref rid="pcbi.1010079.ref067" ref-type="bibr">67</xref>–<xref rid="pcbi.1010079.ref069" ref-type="bibr">69</xref>]. By restoring the precision of prior beliefs, atomoxetine may help attenuate disruptive sensory input [<xref rid="pcbi.1010079.ref070" ref-type="bibr">70</xref>] and minimise the unnecessary updating of prior beliefs in light of spurious prediction errors [<xref rid="pcbi.1010079.ref071" ref-type="bibr">71</xref>,<xref rid="pcbi.1010079.ref072" ref-type="bibr">72</xref>]. Thus, atomoxetine could confer a benefit to Parkinson’s disease patients with reduced noradrenergic capacity, by restoring the reliance on the predictive signals that are necessary for goal-directed behaviour.</p>
              <p>Previous studies have emphasised that the effects of catecholaminergic drugs–including atomoxetine–depend on individual differences in the baseline levels of activity of the ascending neuromodulatory systems [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1010079.ref054" ref-type="bibr">54</xref>–<xref rid="pcbi.1010079.ref056" ref-type="bibr">56</xref>]. However, without specific estimates of locus coeruleus integrity or noradrenergic capacity, heterogeneity in the response to atomoxetine is difficult to interpret [<xref rid="pcbi.1010079.ref038" ref-type="bibr">38</xref>,<xref rid="pcbi.1010079.ref073" ref-type="bibr">73</xref>]. Here, we used ultra-high field imaging to directly quantify the structural integrity of the locus coeruleus in individuals with Parkinson’s disease. Our results indicate that individuals with a more severely degenerated locus coeruleus had a stronger increase in prior weighting following a single dose of atomoxetine, whereas individuals with a relatively preserved locus coeruleus had no meaningful change or even a reduction in prior weighting. These results are consistent with an inverted-U shaped curve of neurotransmitter function, whereby intermediate levels of activity are associated with optimal performance, while hypo- or hyperactive levels lead to suboptimal behaviour [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1010079.ref074" ref-type="bibr">74</xref>,<xref rid="pcbi.1010079.ref075" ref-type="bibr">75</xref>].</p>
              <p>The relationship between locus coeruleus integrity and the drug-induced change in prior weighting varied according to apathy levels. For less apathetic individuals, there was generally no meaningful effect of atomoxetine on prior weighting, and no clear relationship between locus coeruleus integrity and the drug’s effect. In contrast, among more apathetic individuals, we observed a clear baseline-dependent effect of atomoxetine on prior weighting. These results underwrite the multifactorial nature of catecholaminergic drug effects in Parkinson’s disease, with complex interactions between the baseline neuromodulatory state and behavioural symptoms [<xref rid="pcbi.1010079.ref054" ref-type="bibr">54</xref>,<xref rid="pcbi.1010079.ref076" ref-type="bibr">76</xref>]. They also highlight the importance of locus coeruleus imaging for informing noradrenergic therapy: among individuals with apathy, the cognitive effects of atomoxetine varied as a function of locus coeruleus integrity.</p>
              <p>Our results inform theoretical models of noradrenergic function. According to the adaptive gain theory [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>], dynamic shifts between predominantly phasic or tonic modes of locus coeruleus activity modulate the gain of task-relevant brain networks at different timescales, and thereby regulate the balance between task engagement and disengagement [<xref rid="pcbi.1010079.ref077" ref-type="bibr">77</xref>,<xref rid="pcbi.1010079.ref078" ref-type="bibr">78</xref>]. Phasic bursts of locus coeruleus activity, time-locked to task-relevant events, are proposed to induce an adaptive sampling bias, increasing the salience of prepotent representations while inhibiting weaker competing representations. In contrast, persistently elevated (tonic) locus coeruleus activity increases the salience of representations indiscriminately, encouraging task disengagement and exploration [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>] (see also [<xref rid="pcbi.1010079.ref036" ref-type="bibr">36</xref>]). It is possible that individuals with reduced locus coeruleus integrity increase the phasic-to-tonic firing ratio following atomoxetine [<xref rid="pcbi.1010079.ref079" ref-type="bibr">79</xref>], whereas individuals with preserved locus coeruleus integrity were shifted into a predominantly tonic mode of firing. On this basis, an atomoxetine-induced increase in phasic locus coeruleus activity would cause inferences about task performance to be dominated by “optimistic” priors [<xref rid="pcbi.1010079.ref060" ref-type="bibr">60</xref>], neglecting sensory evidence for subtle deviations from this prior [<xref rid="pcbi.1010079.ref080" ref-type="bibr">80</xref>,<xref rid="pcbi.1010079.ref081" ref-type="bibr">81</xref>]. Although this interpretation of the atomoxetine-induced changes in prior weighting remains to be directly tested, it is supported by several lines of evidence. The anterior cingulate and dorsomedial frontal cortex are associated with mechanisms of belief updating [<xref rid="pcbi.1010079.ref041" ref-type="bibr">41</xref>,<xref rid="pcbi.1010079.ref082" ref-type="bibr">82</xref>–<xref rid="pcbi.1010079.ref084" ref-type="bibr">84</xref>]. Reciprocal connections between these regions and the locus coeruleus [<xref rid="pcbi.1010079.ref035" ref-type="bibr">35</xref>,<xref rid="pcbi.1010079.ref085" ref-type="bibr">85</xref>] might therefore enable noradrenergic modulation of the reliance on internal models for action [<xref rid="pcbi.1010079.ref086" ref-type="bibr">86</xref>]. In Parkinson’s disease, locus coeruleus degeneration is accompanied by reduced noradrenaline levels in the forebrain [<xref rid="pcbi.1010079.ref087" ref-type="bibr">87</xref>,<xref rid="pcbi.1010079.ref088" ref-type="bibr">88</xref>]. Atomoxetine increases extracellular noradrenaline levels across the brain–including a three-fold increase in the prefrontal cortex–by inhibiting the presynaptic noradrenaline transporter [<xref rid="pcbi.1010079.ref089" ref-type="bibr">89</xref>,<xref rid="pcbi.1010079.ref090" ref-type="bibr">90</xref>]. Thus, for individuals with severe locus coeruleus degeneration, atomoxetine may help alleviate the dysfunctional modulation of prefrontal noradrenergic targets, and thereby help restore the precision of prefrontal representations of predictive signals.</p>
              <p>This study has limitations. First, although we collected a comprehensive dataset for each individual participant, incorporating various demographic, behavioural, and neuropharmacological measures, the total number of participants is modest. Our study design was therefore not well-suited for data-driven analyses [<xref rid="pcbi.1010079.ref091" ref-type="bibr">91</xref>] or predictive modelling [<xref rid="pcbi.1010079.ref092" ref-type="bibr">92</xref>], and may have been prone to type II error for frequentist statistical inferences on small effects. We focused on the analyses of theory-driven models, with reporting of effect sizes and complementary Bayesian statistics. Second, the participants with Parkinson’s disease were not severely apathetic, as the group mean score on the Apathy Scale fell below conventional cut-off scores for clinically significant apathy [<xref rid="pcbi.1010079.ref001" ref-type="bibr">1</xref>,<xref rid="pcbi.1010079.ref059" ref-type="bibr">59</xref>], and there was no statistically significant difference in apathy between the Parkinson’s disease and control groups. We adopted a dimensional approach [<xref rid="pcbi.1010079.ref017" ref-type="bibr">17</xref>,<xref rid="pcbi.1010079.ref093" ref-type="bibr">93</xref>], focusing on individual differences rather than group contrasts in the mechanisms underlying apathy. Nevertheless, we recognise that it remains to be proven whether the current findings generalise to more severely apathetic cohorts. Third, we acknowledge the psychopharmacological complexity of medicated Parkinson’s disease patients and atomoxetine.</p>
              <p>Due to the limited expression of dopamine transporters in the prefrontal cortex [<xref rid="pcbi.1010079.ref094" ref-type="bibr">94</xref>], a portion of dopamine reuptake is mediated by the noradrenaline transporter [<xref rid="pcbi.1010079.ref095" ref-type="bibr">95</xref>,<xref rid="pcbi.1010079.ref096" ref-type="bibr">96</xref>]. Thus, by blocking the noradrenaline transporter, atomoxetine can increase both noradrenaline and dopamine levels in the prefrontal cortex [<xref rid="pcbi.1010079.ref089" ref-type="bibr">89</xref>,<xref rid="pcbi.1010079.ref097" ref-type="bibr">97</xref>]. It can be challenging to disentangle the noradrenergic versus dopaminergic effects of atomoxetine. Noradrenaline and dopamine are closely related neuromodulators that are synthesised from a shared metabolic pathway. They can be co-released from the same noradrenergic terminals in the prefrontal cortex [<xref rid="pcbi.1010079.ref098" ref-type="bibr">98</xref>,<xref rid="pcbi.1010079.ref099" ref-type="bibr">99</xref>]. Furthermore, locus coeruleus activity can alter midbrain dopamine cell firing [<xref rid="pcbi.1010079.ref100" ref-type="bibr">100</xref>] and contribute to dopamine release in the hippocampus [<xref rid="pcbi.1010079.ref101" ref-type="bibr">101</xref>]. Thus, we cannot wholly exclude the possibility that atomoxetine-induced changes in prior weighting partially reflected dopaminergic effects. However, we note that the integrity of the substantia nigra yielded null results in the model, and including levodopa equivalent daily dose (LEDD) as a covariate did not change the interaction between the drug condition and locus coeruleus CNR on prior weighting. Previous studies similarly found no evidence that the effect of atomoxetine in Parkinson’s disease depends on individual differences in LEDD [<xref rid="pcbi.1010079.ref102" ref-type="bibr">102</xref>]. Future studies could opt for a crossover design with both noradrenergic and dopaminergic agents, to enhance the specificity of findings.</p>
              <p>It is possible that the changes in prior weighting are related to atomoxetine-induced changes in arousal [<xref rid="pcbi.1010079.ref103" ref-type="bibr">103</xref>,<xref rid="pcbi.1010079.ref104" ref-type="bibr">104</xref>]. However, we note that atomoxetine did not affect self-reported levels of arousal [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>], nor did it affect basic task performance in the current study or in a stop-signal task, either at the group-average level or in relation to individual differences in locus coeruleus CNR [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>]. This argues against a simple effect via arousal.</p>
              <p>We used Bayesian inference as a principled framework to model the computational goal of perceptual inference in the context of effortful, goal-directed behaviour. However, we cannot comment directly on the exact algorithmic underpinnings of Bayesian perceptual inference in our experiment [<xref rid="pcbi.1010079.ref105" ref-type="bibr">105</xref>]. Following hierarchical models of predictive coding, one could decompose behaviour in our experiment into predictions at multiple levels of abstraction, from low-level proprioceptive predictions for movement to high-level multi-modal, domain-general beliefs [<xref rid="pcbi.1010079.ref046" ref-type="bibr">46</xref>,<xref rid="pcbi.1010079.ref106" ref-type="bibr">106</xref>–<xref rid="pcbi.1010079.ref111" ref-type="bibr">111</xref>]. Future work is needed to address how such a framework can accommodate the various stages of information processing that are thought to be involved in effort- and reward-based decision-making [<xref rid="pcbi.1010079.ref112" ref-type="bibr">112</xref>–<xref rid="pcbi.1010079.ref114" ref-type="bibr">114</xref>], including the weighting of action policies [<xref rid="pcbi.1010079.ref013" ref-type="bibr">13</xref>,<xref rid="pcbi.1010079.ref015" ref-type="bibr">15</xref>,<xref rid="pcbi.1010079.ref053" ref-type="bibr">53</xref>], initiating and sustaining an action [<xref rid="pcbi.1010079.ref115" ref-type="bibr">115</xref>], and evaluating and learning from the action outcomes.</p>
              <p>We designed this study to test a mechanistic hypothesis about the noradrenergic regulation of sensorimotor integration in Parkinson’s disease. It was not a clinical trial, and we did not focus on clinical outcomes. Further studies are needed to determine if atomoxetine can improve everyday functioning of people with Parkinson’s disease, incorporating patient-, carer- and clinician-rated assessments as well as experimental paradigms [<xref rid="pcbi.1010079.ref016" ref-type="bibr">16</xref>,<xref rid="pcbi.1010079.ref017" ref-type="bibr">17</xref>]. Our results suggest that patients with significant apathy may benefit from noradrenergic treatment, informing future stratified clinical trials.</p>
              <p>In conclusion, this study provides preliminary evidence for a noradrenergic role in apathy in Parkinson’s disease, via the precision weighting of prior beliefs about action outcomes. We suggest that these results support a Bayesian account of apathy as a failure of active inference, resulting from impaired noradrenergic precision of priors for action. The noradrenergic modulation of prior precision may help explain dopamine-insensitive cognitive deficits in Parkinson’s disease, including apathy. Locus coeruleus imaging may offer a useful marker of noradrenergic function that can inform new stratified trials of noradrenergic therapies in selected patients with neurodegenerative disease.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec009">
              <title>Materials and methods</title>
              <sec id="sec010">
                <title>Ethics statement</title>
                <p>The study was approved by the Health Research Authority East of England–Cambridge Central Research Ethics Committee (REC 10/H0308/34), and all participants provided written informed consent in accordance with the Declaration of Helsinki.</p>
                <p>The current study was part of a broader project on the noradrenergic mechanisms of cognitive and motivational problems in Parkinson’s disease, including response inhibition deficits, as reported in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>]. Therefore, the following description of the participants, study procedure, and locus coeruleus imaging overlaps with the Methods section in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>].</p>
              </sec>
              <sec id="sec011">
                <title>Participants</title>
                <p>Eighteen people with idiopathic Parkinson’s disease were recruited via the University of Cambridge Parkinson’s disease research clinic and through Parkinson’s UK volunteer panels. All participants met the United Kingdom Parkinson’s Disease Society Brain Bank criteria, were aged between 50–80 years, and had no contraindications to 7T MRI or atomoxetine. No participants had dementia, based on the Movement Disorder Society criteria for Parkinson’s disease dementia [<xref rid="pcbi.1010079.ref116" ref-type="bibr">116</xref>] and the mini-mental state examination (score &gt; 26)[<xref rid="pcbi.1010079.ref117" ref-type="bibr">117</xref>]. None had current impulse control disorders, based on clinical impression and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP-Current Short) screening tool [<xref rid="pcbi.1010079.ref118" ref-type="bibr">118</xref>]. Levodopa equivalent daily dose (LEDD) was calculated according to Tomlinson et al. [<xref rid="pcbi.1010079.ref058" ref-type="bibr">58</xref>].</p>
                <p>Twenty-one age-, sex- and education-matched healthy controls were recruited from local volunteer panels, to provide normative data. They had no history of neurological or psychiatric disorders, and were not using psychoactive medications.</p>
                <p>One control participant and one participant with Parkinson’s disease had excessive amounts of missing visuomotor task data (≥ 50% of trials) due to technical issues. After excluding these participants, the final sample consisted of 17 participants with Parkinson’s disease and 20 controls. Demographic details and clinical characteristics are provided in <xref rid="pcbi.1010079.t001" ref-type="table">Table 1</xref> and <xref rid="pcbi.1010079.s006" ref-type="supplementary-material">S1 Text</xref>.</p>
              </sec>
              <sec id="sec012">
                <title>Study procedure</title>
                <p>Participants with Parkinson’s disease were tested across three sessions. The first session consisted of MRI scanning and clinical assessment, including the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA) and the revised Addenbrooke’s cognitive examination (ACE-R).</p>
                <p>The second and third sessions formed a double-blind randomised placebo-controlled crossover study, with 40 mg of oral atomoxetine or placebo. The 40 mg atomoxetine dose is widely used as a well-tolerated ‘starter dose’ [<xref rid="pcbi.1010079.ref119" ref-type="bibr">119</xref>,<xref rid="pcbi.1010079.ref120" ref-type="bibr">120</xref>] that is capable of modulating behaviour and brain function in Parkinson’s disease [<xref rid="pcbi.1010079.ref029" ref-type="bibr">29</xref>,<xref rid="pcbi.1010079.ref102" ref-type="bibr">102</xref>]. The drug order was pseudorandomly permuted in blocks of six successive participants, to ensure that the order was balanced across the group. This means that three participants were pseudorandomly assigned to the placebo-atomoxetine order and three to the atomoxetine-placebo order within each block of the 1<sup>st</sup>– 6<sup>th</sup>, 7<sup>th</sup>– 12<sup>th</sup>, and 13<sup>th</sup>– 18<sup>th</sup> participants. The sessions were scheduled at least 6 days apart (M = 7.29 days, SD = 1.76 days, range: 6–14 days) and at a similar time of day. For each session, blood samples were taken two hours after drug administration, to coincide with predicted peak plasma concentration of atomoxetine after a single oral dose [<xref rid="pcbi.1010079.ref121" ref-type="bibr">121</xref>]. Mean plasma concentration [<xref rid="pcbi.1010079.ref122" ref-type="bibr">122</xref>] was 264.07 ng/mL after atomoxetine (SD = 124.50 ng/mL, range: 90.92–595.11 ng/mL) and 0 ng/mL after placebo. After the blood sample, participants completed an experimental task battery that included a visuomotor task, which is the focus of the current manuscript. Participants were on their regular anti-parkinsonian medications throughout the study.</p>
                <p>Control participants were tested in a single session that included MRI scanning and the same experimental task battery as the participants with Parkinson’s disease. The control group did not undergo the drug manipulation.</p>
                <p>All participants completed a set of questionnaires that assessed mood and various behavioural symptoms. With the exception of the Apathy Scale [<xref rid="pcbi.1010079.ref059" ref-type="bibr">59</xref>], these questionnaires were primarily collected for demographic purposes, and are described in detail in <xref rid="pcbi.1010079.s006" ref-type="supplementary-material">S1 Text</xref>.</p>
              </sec>
              <sec id="sec013">
                <title>Visuomotor task</title>
                <p>We administered a visuomotor task (adapted from Hezemans et al. [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>]) that involved effortful, goal-directed behaviour, and required participants to estimate their own performance. For each trial, participants pressed on a force sensor for 3 seconds using the index finger of their dominant hand, to subsequently trigger a ballistic ball movement on the screen, aiming for the ball to stop on the target. The force response was defined as the mean force exerted from 1.5 to 2.5 seconds, divided by the participant’s maximum force (estimated separately, see below). The initial velocity of the ball increased monotonically with the force response. The deceleration of the ball was kept constant. Thus, the relative force exerted on the sensor (i.e., the initial velocity) directly determined the ball’s final position. As a measure of basic task performance, we calculated the force error, defined as the difference between the force response and the force required to stop the ball perfectly on target.</p>
                <p>The task consisted of two types of trials: basic trials and estimation trials. For basic trials, participants viewed the outcome of their action–that is, the ball’s full trajectory to its final position on the screen. The difference between the ball’s final position and the target constituted the performance error, expressed in pixels.</p>
                <sec id="sec014">
                  <title>Estimating task performance</title>
                  <p>For estimation trials, the ball’s trajectory was not shown, and participants were asked to estimate where the ball would have stopped. Participants were shown a grid of 12 evenly spaced response options (labelled with numbers 1 to 12), where one of the response options was centred on the true final ball position (i.e. the veridical response option). Participants verbally indicated their belief about the ball’s final location to the experimenter as a digit (“one” to “twelve”). The difference between the selected response option and the veridical response option constituted the estimation error. Note that the target was not shown during the estimation procedure, and participants did not receive feedback regarding the true final ball position on estimation trials.</p>
                  <p>For each estimation trial, the veridical response option was selected pseudorandomly from a uniform distribution between 3 and 10. This ensured that the absolute position of the estimation grid was not indicative of the true final ball position, and that there were sufficient response options both to the left and right of the true final ball position. The width of the estimation grid was 30% of the screen width. Note that in our previous work using an unconstrained (mouse cursor) estimation procedure [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>], the standard deviation of estimation error was 6.80% of the screen width.</p>
                </sec>
                <sec id="sec015">
                  <title>Task procedure</title>
                  <p>The task started with a practice block of 15 basic trials. In the last 5 of these practice trials, participants were asked to estimate their performance after observing the full ball trajectory, to introduce the estimation procedure. The experimenter verified that the participant understood the estimation procedure, and if necessary the practice block was repeated. The practice data was not analysed further. The subsequent test phase consisted of 4 blocks of 30 trials each. Each block consisted of 20 basic trials and 10 estimation trials. The trials within each block were pseudorandomly interleaved, with the constraints that the first 3 trials were always basic trials and that there could not be two consecutive estimation trials. In total, each testing session consisted of 120 trials, of which 40 were estimation trials. To minimise potential effects of fatigue on task performance, participants were given the opportunity to take a short break after each block.</p>
                  <p>For consistency with the original study design in Hezemans et al. [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>], the task additionally featured experimental manipulations of effort and reward. Physical effort was manipulated by displaying the target either relatively close to or far from the ball’s starting position, corresponding to 35% or 65% of the participant’s maximum force. Reward was manipulated by either giving participants points (tallied at the top of the screen) in relation to their performance on basic trials, or not giving any points. We used a 2 × 2 factorial design (low effort vs. high effort; no reward vs. reward) with one block of 30 trials for each combination of effort and reward. Following the results of Hezemans et al. [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>], showing minimal effects of effort and reward on prior weighting that were not associated with apathy, we report the effects of these conditions on behaviour in <xref rid="pcbi.1010079.s009" ref-type="supplementary-material">S4 Text</xref>.</p>
                </sec>
                <sec id="sec016">
                  <title>Maximum force calibration</title>
                  <p>We established each participant’s maximum force at the start of the task, so that the relative level of force required could be fixed across participants. Participants pressed with the maximum force they could sustain for 10 seconds. The mean force within a 5 second window with the lowest variance was taken as the response. This procedure was repeated three times, and the highest value across iterations was taken as the participant’s maximum force.</p>
                </sec>
              </sec>
              <sec id="sec017">
                <title>Bayesian modelling of performance estimates</title>
                <p>The estimation trials in our visuomotor task can be considered as a Bayesian inference problem [<xref rid="pcbi.1010079.ref123" ref-type="bibr">123</xref>,<xref rid="pcbi.1010079.ref124" ref-type="bibr">124</xref>], where for each trial <italic toggle="yes">n</italic> participants infer a hidden variable <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup> given noisy sensory evidence <italic toggle="yes">s</italic><sup>(<italic toggle="yes">n</italic>)</sup>:
<disp-formula id="pcbi.1010079.e009"><alternatives><graphic xlink:href="pcbi.1010079.e009.jpg" id="pcbi.1010079.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder><mml:mo>∝</mml:mo><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:munder><mml:mo>∙</mml:mo><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder></mml:math></alternatives><label>(4)</label></disp-formula></p>
                <p>The sensory evidence <italic toggle="yes">s</italic><sup>(<italic toggle="yes">n</italic>)</sup> is assumed to be the true value of the hidden variable <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup> corrupted by sensory noise, <italic toggle="yes">s</italic><sup>(<italic toggle="yes">n</italic>)</sup> = <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup>+<italic toggle="yes">ϵ</italic><sup>(<italic toggle="yes">n</italic>)</sup>, where the noise <italic toggle="yes">ϵ</italic><sup>(<italic toggle="yes">n</italic>)</sup> is sampled from a Gaussian distribution with zero mean and variance <inline-formula id="pcbi.1010079.e010"><alternatives><graphic xlink:href="pcbi.1010079.e010.jpg" id="pcbi.1010079.e010g" position="anchor"/><mml:math id="M10" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, that is <inline-formula id="pcbi.1010079.e011"><alternatives><graphic xlink:href="pcbi.1010079.e011.jpg" id="pcbi.1010079.e011g" position="anchor"/><mml:math id="M11" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>∼</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>. Thus, the likelihood is assumed to follow a Gaussian distribution with mean <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup> and variance <inline-formula id="pcbi.1010079.e012"><alternatives><graphic xlink:href="pcbi.1010079.e012.jpg" id="pcbi.1010079.e012g" position="anchor"/><mml:math id="M12" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>. The prior on <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup> is assumed to follow a Gaussian distribution with mean <inline-formula id="pcbi.1010079.e013"><alternatives><graphic xlink:href="pcbi.1010079.e013.jpg" id="pcbi.1010079.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and variance <inline-formula id="pcbi.1010079.e014"><alternatives><graphic xlink:href="pcbi.1010079.e014.jpg" id="pcbi.1010079.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>. Taken together, the posterior of <italic toggle="yes">x</italic><sup>(<italic toggle="yes">n</italic>)</sup> is proportional to the product of two Gaussian distributions:
<disp-formula id="pcbi.1010079.e015"><alternatives><graphic xlink:href="pcbi.1010079.e015.jpg" id="pcbi.1010079.e015g" position="anchor"/><mml:math id="M15" display="block" overflow="scroll"><mml:mi>p</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mo>)</mml:mo><mml:mo>∝</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>;</mml:mo><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo><mml:mo>∙</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>;</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives><label>(5)</label></disp-formula></p>
                <p>The optimal estimate of the hidden variable, <inline-formula id="pcbi.1010079.e016"><alternatives><graphic xlink:href="pcbi.1010079.e016.jpg" id="pcbi.1010079.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>, minimises the expected loss <inline-formula id="pcbi.1010079.e017"><alternatives><graphic xlink:href="pcbi.1010079.e017.jpg" id="pcbi.1010079.e017g" position="anchor"/><mml:math id="M17" display="inline" overflow="scroll"><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> given the sensory evidence. Since the posterior distribution in <xref rid="pcbi.1010079.e015" ref-type="disp-formula">Eq 5</xref> is Gaussian, its mean, median, and mode have the same value. We can therefore assume without loss of generality that the optimal estimate equals the posterior mean [<xref rid="pcbi.1010079.ref125" ref-type="bibr">125</xref>], which is a precision-weighted sum of the sampled sensory evidence and the prior mean:
<disp-formula id="pcbi.1010079.e018"><alternatives><graphic xlink:href="pcbi.1010079.e018.jpg" id="pcbi.1010079.e018g" position="anchor"/><mml:math id="M18" display="block" overflow="scroll"><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:munder><mml:mspace width="0.25em"/><mml:mi mathvariant="double-struck">E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="script">L</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>|</mml:mo><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>]</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="pcbi.1010079.e019"><alternatives><graphic xlink:href="pcbi.1010079.e019.jpg" id="pcbi.1010079.e019g" position="anchor"/><mml:math id="M19" display="block" overflow="scroll"><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>∙</mml:mo><mml:msup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives><label>(6)</label></disp-formula></p>
                <sec id="sec018">
                  <title>Estimating prior weighting</title>
                  <p>In the current study, we assume that the sensory evidence is centred on the true final ball position <inline-formula id="pcbi.1010079.e020"><alternatives><graphic xlink:href="pcbi.1010079.e020.jpg" id="pcbi.1010079.e020g" position="anchor"/><mml:math id="M20" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> with variance <inline-formula id="pcbi.1010079.e021"><alternatives><graphic xlink:href="pcbi.1010079.e021.jpg" id="pcbi.1010079.e021g" position="anchor"/><mml:math id="M21" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, and the prior is centred on the target position <inline-formula id="pcbi.1010079.e022"><alternatives><graphic xlink:href="pcbi.1010079.e022.jpg" id="pcbi.1010079.e022g" position="anchor"/><mml:math id="M22" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> with variance <inline-formula id="pcbi.1010079.e023"><alternatives><graphic xlink:href="pcbi.1010079.e023.jpg" id="pcbi.1010079.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>. The observed estimate of performance <inline-formula id="pcbi.1010079.e024"><alternatives><graphic xlink:href="pcbi.1010079.e024.jpg" id="pcbi.1010079.e024g" position="anchor"/><mml:math id="M24" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> can then be modelled as the sum of <inline-formula id="pcbi.1010079.e025"><alternatives><graphic xlink:href="pcbi.1010079.e025.jpg" id="pcbi.1010079.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1010079.e026"><alternatives><graphic xlink:href="pcbi.1010079.e026.jpg" id="pcbi.1010079.e026g" position="anchor"/><mml:math id="M26" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>n</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, weighted by their inverse variances:
<disp-formula id="pcbi.1010079.e027"><alternatives><graphic xlink:href="pcbi.1010079.e027.jpg" id="pcbi.1010079.e027g" position="anchor"/><mml:math id="M27" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives><label>(1 restated)</label></disp-formula></p>
                  <p>The prior weighting term, <inline-formula id="pcbi.1010079.e028"><alternatives><graphic xlink:href="pcbi.1010079.e028.jpg" id="pcbi.1010079.e028g" position="anchor"/><mml:math id="M28" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:math></alternatives></inline-formula>, can be estimated as the negative of the regression coefficient of estimation error on performance error [<xref rid="pcbi.1010079.ref060" ref-type="bibr">60</xref>]:
<disp-formula id="pcbi.1010079.e029"><alternatives><graphic xlink:href="pcbi.1010079.e029.jpg" id="pcbi.1010079.e029g" position="anchor"/><mml:math id="M29" display="block" overflow="scroll"><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>∙</mml:mo><mml:munder><mml:mrow><mml:munder accentunder="false"><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>︸</mml:mo></mml:munder></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:munder></mml:math></alternatives><label>(3 restated)</label></disp-formula></p>
                  <p>We used a linear mixed effects model to fit the linear relationship between estimation errors and performance errors, allowing the slope to vary for each of the 54 completed testing sessions (20 control participants plus 17 participants with Parkinson’s disease tested twice). Prior to model fitting, the estimation errors and performance errors were z-scored for each testing session, to bring these variables onto a common scale and to ensure that the intercept was zero, as assumed by the model (<xref rid="pcbi.1010079.e008" ref-type="disp-formula">Eq 3</xref>). We performed a parameter recovery analysis to ensure that this analysis procedure could reliably identify data-generating parameter values, given our experimental design and model assumptions (<xref rid="pcbi.1010079.s010" ref-type="supplementary-material">S5 Text</xref>).</p>
                </sec>
                <sec id="sec019">
                  <title>Hierarchical Bayesian modelling of estimation trials</title>
                  <p>The observed estimate of performance can alternatively be modelled probabilistically, as a sample from the full posterior distribution:
<disp-formula id="pcbi.1010079.e030"><alternatives><graphic xlink:href="pcbi.1010079.e030.jpg" id="pcbi.1010079.e030g" position="anchor"/><mml:math id="M30" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:math></alternatives><label>(7)</label></disp-formula>
where the posterior variance <inline-formula id="pcbi.1010079.e031"><alternatives><graphic xlink:href="pcbi.1010079.e031.jpg" id="pcbi.1010079.e031g" position="anchor"/><mml:math id="M31" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula> is given by:
<disp-formula id="pcbi.1010079.e032"><alternatives><graphic xlink:href="pcbi.1010079.e032.jpg" id="pcbi.1010079.e032g" position="anchor"/><mml:math id="M32" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>∙</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:math></alternatives><label>(8)</label></disp-formula></p>
                  <p>By explicitly modelling the posterior variance, the prior and sensory evidence variances can be separately identified. For example, although an increase in prior variance or a decrease in sensory evidence variance could have the same effect on prior weighting (<xref rid="pcbi.1010079.e007" ref-type="disp-formula">Eq 2</xref>), these changes would have dissociable effects on the posterior variance (<xref rid="pcbi.1010079.e032" ref-type="disp-formula">Eq 8</xref>).</p>
                  <p>Potential drug effects on the prior and sensory evidence variances were modelled as atomoxetine-induced changes (Δ) in these parameters, relative to the placebo session. For example, the standard deviation of the prior for participant <italic toggle="yes">i</italic> in session <italic toggle="yes">j</italic> was defined as follows:
<disp-formula id="pcbi.1010079.e033"><alternatives><graphic xlink:href="pcbi.1010079.e033.jpg" id="pcbi.1010079.e033g" position="anchor"/><mml:math id="M33" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mspace width="5.25em"/><mml:mi mathvariant="normal">if</mml:mi><mml:mspace width="0.25em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">placebo</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mspace width="1em"/><mml:mi mathvariant="normal">if</mml:mi><mml:mspace width="0.25em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">atomoxetine</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives><label>(9)</label></disp-formula></p>
                  <p>We additionally accounted for any consistent spatial shifts in the sensory evidence, <italic toggle="yes">x</italic><sub>shift</sub>, to relax the assumption that the trial-wise sensory evidence distribution was centred on the true final ball position [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>,<xref rid="pcbi.1010079.ref060" ref-type="bibr">60</xref>,<xref rid="pcbi.1010079.ref126" ref-type="bibr">126</xref>]:
<disp-formula id="pcbi.1010079.e034"><alternatives><graphic xlink:href="pcbi.1010079.e034.jpg" id="pcbi.1010079.e034g" position="anchor"/><mml:math id="M34" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:math></alternatives><label>(10)</label></disp-formula></p>
                  <p>The model consisted of five free parameters in total: <italic toggle="yes">σ</italic><sub>prior</sub>, <italic toggle="yes">σ</italic><sub>evidence</sub>, Δ<sub>prior</sub>, Δ<sub>evidence</sub>, and <italic toggle="yes">x</italic><sub>shift</sub>. We estimated these parameters hierarchically, such that parameters for a given participant <italic toggle="yes">i</italic> were sampled from corresponding group-level distributions:
<disp-formula id="pcbi.1010079.e035"><alternatives><graphic xlink:href="pcbi.1010079.e035.jpg" id="pcbi.1010079.e035g" position="anchor"/><mml:math id="M35" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">N</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="pcbi.1010079.e036"><alternatives><graphic xlink:href="pcbi.1010079.e036.jpg" id="pcbi.1010079.e036g" position="anchor"/><mml:math id="M36" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="script">N</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="pcbi.1010079.e037"><alternatives><graphic xlink:href="pcbi.1010079.e037.jpg" id="pcbi.1010079.e037g" position="anchor"/><mml:math id="M37" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="pcbi.1010079.e038"><alternatives><graphic xlink:href="pcbi.1010079.e038.jpg" id="pcbi.1010079.e038g" position="anchor"/><mml:math id="M38" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
<disp-formula id="pcbi.1010079.e039"><alternatives><graphic xlink:href="pcbi.1010079.e039.jpg" id="pcbi.1010079.e039g" position="anchor"/><mml:math id="M39" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∼</mml:mo><mml:mi mathvariant="script">N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:math></alternatives><label>(11)</label></disp-formula>
where <inline-formula id="pcbi.1010079.e040"><alternatives><graphic xlink:href="pcbi.1010079.e040.jpg" id="pcbi.1010079.e040g" position="anchor"/><mml:math id="M40" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi mathvariant="script">N</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> denotes a Gaussian distribution that is truncated to only allow positive values. We generally assigned relatively broad (“weakly informative”) prior distributions on the group-level means and variances of the model parameters. The priors on <inline-formula id="pcbi.1010079.e041"><alternatives><graphic xlink:href="pcbi.1010079.e041.jpg" id="pcbi.1010079.e041g" position="anchor"/><mml:math id="M41" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>Δ</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1010079.e042"><alternatives><graphic xlink:href="pcbi.1010079.e042.jpg" id="pcbi.1010079.e042g" position="anchor"/><mml:math id="M42" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> were all centred on zero–that is, we conservatively assumed <italic toggle="yes">a priori</italic> that on average there would be no drug effects or spatial shift. Further details about the model specification are provided in <xref rid="pcbi.1010079.s002" ref-type="supplementary-material">S2 Fig</xref>. Our primary interest was in the participant-level estimates of drug effects on the standard deviation of the prior and sensory evidence distributions.</p>
                  <p>We additionally fit three variants of this model, where the prior and / or sensory evidence standard deviation parameters were constrained to be fixed across the placebo and atomoxetine sessions. Specifically, one model variant only allowed for drug effects on the prior standard deviation, another model variant only allowed for drug effects on sensory evidence standard deviation, and a final model variant did not include any drug-induced change parameters. However, a comparison of each model’s estimated pointwise predictive accuracy [<xref rid="pcbi.1010079.ref127" ref-type="bibr">127</xref>] favoured the inclusion of drug effects on both the prior and sensory evidence standard deviations (<xref rid="pcbi.1010079.s003" ref-type="supplementary-material">S3 Fig</xref>), and we therefore focused on the parameter estimates from the ‘full’ model.</p>
                  <p>We used Markov Chain Monte Carlo (MCMC) sampling to estimate the posterior distributions of the model parameters. We used 8 chains with 4000 samples each, and discarded the first 2000 samples of each chain as the warm-up. Model convergence was confirmed by the potential scale reduction statistic <inline-formula id="pcbi.1010079.e043"><alternatives><graphic xlink:href="pcbi.1010079.e043.jpg" id="pcbi.1010079.e043g" position="anchor"/><mml:math id="M43" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:math></alternatives></inline-formula> (&lt; 1.004 for all parameters), and by visual inspection of the time-series plots of the MCMC samples. The model’s goodness of fit was assessed by visually comparing the observed data to simulated data generated from the model’s posterior predictive distribution (<xref rid="pcbi.1010079.s004" ref-type="supplementary-material">S4</xref> and <xref rid="pcbi.1010079.s005" ref-type="supplementary-material">S5</xref> Figs). For a given parameter of interest, we took the median of its posterior distribution as the optimal estimate.</p>
                </sec>
              </sec>
              <sec id="sec020">
                <title>MRI acquisition</title>
                <p>The MR images were acquired with a 7T Magnetom Terra (Siemens, Erlangen, Germany), using a 32-channel head coil (Nova Medical, Wilmington, USA). The locus coeruleus was imaged using a 3D magnetisation transfer (MT) weighted sequence at high resolution [<xref rid="pcbi.1010079.ref057" ref-type="bibr">57</xref>,<xref rid="pcbi.1010079.ref128" ref-type="bibr">128</xref>]. The sequence included 112 oblique, axial slices oriented perpendicular to the long axis of the brainstem, to cover both the midbrain and the pontine regions. A train of 20 Gaussian-shaped RF pulses was applied at 6.72 ppm off resonance, 420° flip angle, followed by a turbo-flash readout (TE = 4.08 ms, TR = 1251 ms, flip-angle = 8°, voxel size = 0.4 x 0.4 x 0.5 mm<sup>3</sup>, 6/8 phase and slice partial Fourier, bandwidth = 140 Hz/px, no acceleration, 14.3%- oversampling, TA ~ 7 min). The transmit voltage was adjusted for each participant based on the average flip angle in the central area of the pons, which was obtained from a B1 pre-calibration scan. The MT scan was repeated twice and averaged offline to enhance the signal-to-noise ratio. An additional scan was acquired with the same parameters as above but without the off-resonance pulses. For anatomical coregistration, a high resolution T1-weighted structural image (0.7 mm isotropic) was acquired using the MP2RAGE sequence with the UK7T Network harmonised protocol: TE = 2.58 ms, TR = 3500 ms, BW = 300 Hz/px, voxel size = 0.7 x 0.7 x 0.7 mm<sup>3</sup>, FoV = 224 x 224 x 157 mm<sup>3</sup>, acceleration factor (A&gt;&gt;P) = 3, flip angles = 5/2° and inversion times (TI) = 725/2150 ms for the first/second images.</p>
              </sec>
              <sec id="sec021">
                <title>Image processing and locus coeruleus integrity</title>
                <p>The image processing pipeline is described in detail in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>], which used an identical pipeline as the current study (based on Ye et al. [<xref rid="pcbi.1010079.ref057" ref-type="bibr">57</xref>]). The MT images were bias field corrected, and then entered into a T1-driven coregistration pipeline to warp the images to the isotropic 0.5 mm ICBM152 (International Consortium for Brain Mapping) T1-weighted asymmetric template [<xref rid="pcbi.1010079.ref129" ref-type="bibr">129</xref>].</p>
                <p>The co-registered MT images were used to quantify the contrast with respect to a reference region, the central pontine tegmentum, generating contrast-to-noise ratio (CNR) maps. For each participant <italic toggle="yes">i</italic> and voxel <italic toggle="yes">j</italic>, the signal <italic toggle="yes">x</italic><sup>(<italic toggle="yes">i</italic>,<italic toggle="yes">j</italic>)</sup> was contrasted with the mean reference signal <inline-formula id="pcbi.1010079.e044"><alternatives><graphic xlink:href="pcbi.1010079.e044.jpg" id="pcbi.1010079.e044g" position="anchor"/><mml:math id="M44" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>, and then divided by the standard deviation of the reference signal <inline-formula id="pcbi.1010079.e045"><alternatives><graphic xlink:href="pcbi.1010079.e045.jpg" id="pcbi.1010079.e045g" position="anchor"/><mml:math id="M45" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:math></alternatives></inline-formula>:
<disp-formula id="pcbi.1010079.e046"><alternatives><graphic xlink:href="pcbi.1010079.e046.jpg" id="pcbi.1010079.e046g" position="anchor"/><mml:math id="M46" display="block" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:math></alternatives><label>(12)</label></disp-formula></p>
                <p>To ensure that the CNR values were localised to the locus coeruleus, we used an independent locus coeruleus atlas based on a separate sample of 29 age- and education-matched healthy controls [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>]. For each axial slice on the rostrocaudal extent, the locations of the left and right locus coeruleus were determined using a semi-automated segmentation method [<xref rid="pcbi.1010079.ref057" ref-type="bibr">57</xref>]. The locus coeruleus voxels were segmented into binary images, and then averaged and thresholded at 5% to obtain a template (705 voxels, 88.125 mm<sup>3</sup>; see Supplementary Materials in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>]).</p>
                <p>To estimate the locus coeruleus integrity, we applied the independent locus coeruleus atlas to each participant’s CNR map, and then calculated the mean CNR value across the whole structure. We also performed this calculation after applying a more stringent locus coeruleus atlas that was thresholded at 25% (274 voxels, 34.25 mm<sup>3</sup>). In addition, we performed an alternative calculation of locus coeruleus contrast that replaced the denominator in <xref rid="pcbi.1010079.e046" ref-type="disp-formula">Eq 12</xref> with the mean reference signal: <inline-formula id="pcbi.1010079.e047"><alternatives><graphic xlink:href="pcbi.1010079.e047.jpg" id="pcbi.1010079.e047g" position="anchor"/><mml:math id="M47" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math></alternatives></inline-formula>, yielding a contrast ratio rather than contrast-to-noise ratio. However, as described in the Results section, these alternative contrast methods did not meaningfully change the relationship between locus coeruleus integrity and the atomoxetine-induced change in prior weighting. Comparisons of locus coeruleus CNR between the Parkinson’s disease and control groups are reported in detail in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>].</p>
                <p>We used an analogous approach to obtain CNR from the substantia nigra, as a neuromelanin-rich control region. This analysis pipeline is described in detail in the Supplementary Materials in O’Callaghan et al. [<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>] and in Rua et al. [<xref rid="pcbi.1010079.ref063" ref-type="bibr">63</xref>]. In brief, the MT images from the separate sample of 29 age- and education-matched healthy controls were used to create an independent probabilistic atlas of the substantia nigra, thresholded at 5%. This atlas was then applied to the current study sample to compute a CNR map (<xref rid="pcbi.1010079.e046" ref-type="disp-formula">Eq 12</xref>), where the reference region was defined as the midbrain background (<italic toggle="yes">crus cerebri</italic>). The mean CNR value for each participant served as the estimate of substantia nigra CNR.</p>
              </sec>
              <sec id="sec022">
                <title>Statistical inference</title>
                <p>We report both frequentist and Bayes factor (BF) analyses for hypothesis testing, with a significance threshold of <italic toggle="yes">p</italic> = .05 (two-sided) for frequentist analyses. We present the BF for the alternative hypothesis over the null hypothesis (i.e., BF<sub>10</sub>), such that BF &gt; 3 indicates “positive evidence” for the alternative hypothesis. All BF analyses used the default ‘JZS’ prior on the effect size under the alternative hypothesis. To obtain BFs for specific effects in ANOVAs and linear (mixed) models, we used Bayesian model averaging to estimate the change from prior to posterior inclusion odds (“inclusion BF”). This BF indicates how much more likely the data are when a given effect is included in the model, compared to when the effect is excluded [<xref rid="pcbi.1010079.ref130" ref-type="bibr">130</xref>]. The <italic toggle="yes">p</italic>-values for fixed effects in linear mixed models were obtained using the Kenward-Roger approximation. Prior to analyses, we z-scored all continuous variables, and assigned sum-to-zero contrasts to categorical variables.</p>
              </sec>
              <sec id="sec023">
                <title>Software and equipment</title>
                <p>The visuomotor task was implemented in <sc>Matlab</sc> R2018b using the Psychophysics Toolbox extensions version 3 [<xref rid="pcbi.1010079.ref131" ref-type="bibr">131</xref>], and was displayed on a 12.5-inch laptop screen (1920 × 1080 pixels). The force sensor had a sampling rate of 60 Hz and a measurement accuracy of ±9.8 mN. The magnetisation transfer images were processed using the Advanced Normalization Tools version 2.2.0 [<xref rid="pcbi.1010079.ref132" ref-type="bibr">132</xref>] and in-house <sc>Matlab</sc> scripts [<xref rid="pcbi.1010079.ref057" ref-type="bibr">57</xref>,<xref rid="pcbi.1010079.ref062" ref-type="bibr">62</xref>]. All statistical analyses were implemented in R version 3.6.1 [<xref rid="pcbi.1010079.ref133" ref-type="bibr">133</xref>]; detailed information about the specific R packages used for the analyses is provided in <xref rid="pcbi.1010079.s011" ref-type="supplementary-material">S6 Text</xref>. The hierarchical Bayesian modelling was implemented in Stan [<xref rid="pcbi.1010079.ref134" ref-type="bibr">134</xref>].</p>
              </sec>
            </sec>
            <sec id="sec024" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pcbi.1010079.s001" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>Relationship between prior weighting and apathy in young adults.</title>
                  <p>Data from Hezemans et al. [<xref rid="pcbi.1010079.ref043" ref-type="bibr">43</xref>], demonstrating the relationship between trait apathy (measured using the Apathy Motivation Index) and prior weighting, adjusted for task performance variability (i.e., partial residuals). Note that observations with identical questionnaire scores were horizontally jittered to avoid overlaid dots. Full statistics for the regression coefficient of apathy: β = -0.42, SE = 0.14, <italic toggle="yes">t</italic>(44) = -3.02, <italic toggle="yes">p</italic> = .004; BF = 11.63.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s002" position="float" content-type="local-data">
                <label>S2 Fig</label>
                <caption>
                  <title>Plate notation and sampling statements for the hierarchical Bayesian model.</title>
                  <p>Participant-level parameters were sampled from latent group-level distributions. We allowed for atomoxetine-induced changes in the standard deviations of the prior and sensory evidence distributions. Session-level parameters were then used to obtain trial-level posterior distributions of the final ball position. The observed estimates of performance were modelled as samples from the trial-level posterior distributions. The model is represented in plate notation: shaded nodes represent observed data whereas white nodes represent latent variables; rectangular nodes represent discrete or fixed variables whereas circular nodes represent continuous variables; and double-bordered white nodes represent deterministic variables whereas single-bordered white nodes represent stochastic variables.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s003" position="float" content-type="local-data">
                <label>S3 Fig</label>
                <caption>
                  <title>Information criteria for variants of the hierarchical Bayesian model.</title>
                  <p>In addition to the model presented in the manuscript, we fit three variants of the model with restrictions on the number of drug-induced change parameters. For each model variant, we computed the leave-one-out information criterion (LOOIC) and the widely applicable information criterion (WAIC) as estimates of the model’s expected predictive accuracy. For both measures, the ‘full’ model which included drug-induced change parameters for both the prior and sensory evidence standard deviations was strongly preferred over the three more restricted model variants.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s004" position="float" content-type="local-data">
                <label>S4 Fig</label>
                <caption>
                  <title>Posterior predictive check: response distributions.</title>
                  <p>Each panel compares the observed responses (light-coloured density plot and histogram) to distributions of simulated responses drawn from the model’s posterior predictive distribution (dark-coloured density traces).</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s005" position="float" content-type="local-data">
                <label>S5 Fig</label>
                <caption>
                  <title>Posterior predictive check: predictive error.</title>
                  <p>Each panel illustrates the distribution of the mean predictive error of the model–that is, the observed responses minus simulated responses drawn from the model’s posterior predictive distribution, averaged across Markov Chain Monte Carlo samples. These histograms can therefore be interpreted as the distributions of residuals.</p>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s005.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s006" position="float" content-type="local-data">
                <label>S1 Text</label>
                <caption>
                  <title>Mood and behaviour questionnaires.</title>
                  <p><bold>Table A. Descriptive statistics and group comparisons of questionnaires.</bold> Data are presented as mean (SD). Group comparisons were performed with independent samples t-tests. The stated p-values are uncorrected; none survived p &lt; .05 after correction for multiple comparisons. Abbreviations: BF, Bayes Factor for the alternative hypothesis over the null hypothesis, where &gt; 3 would indicate positive evidence in favour of a group difference; BIS, Barratt Impulsiveness Scale; HADS, Hospital Anxiety and Depression Scale; MEI, Motivation and Energy Inventory; CAARS, Conners’ Adult ADHD Rating Scale; RBDSQ, REM sleep Behaviour Disorder Screening Questionnaire; CBI-R, Cambridge Behavioural Inventory–Revised. <bold>Fig A. Density plots of questionnaire scores for participants with Parkinson’s disease (blue) and controls (orange).</bold> The questionnaire scores were z-scored to bring the different questionnaires onto a common scale (note that this transformation does not affect group comparisons for a given questionnaire outcome). Tick marks reflect individual data points. Abbreviations: BIS, Barratt Impulsiveness Scale; MEI, Motivation and Energy Inventory; HADS, Hospital Anxiety and Depression Scale; CAARS, Conners’ Adult ADHD Rating Scale.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s007" position="float" content-type="local-data">
                <label>S2 Text</label>
                <caption>
                  <title>Role of covariates in the drug × LC CNR interaction on prior weighting.</title>
                  <p><bold>Table A. Backward elimination of fixed effects in the linear mixed effects model predicting prior weighting.</bold> Values for predictors are standardised regression coefficients (ß). *<italic toggle="yes">p</italic> &lt; .05. Drug, atomoxetine vs. placebo condition; LC CNR, Locus Coeruleus Contrast to Noise Ratio; ICV, total intracranial volume; Ato plasma, atomoxetine plasma concentration; LEDD, Levodopa Equivalent Daily Dose; Session, first vs. second session; UPDRS III, Unified Parkinson’s Disease Rating Scale, motor examination; AIC, Akaike Information Criterion; BIC, Bayesian Information Criterion; Δ AIC / BIC, difference in AIC / BIC with respect to the lowest AIC / BIC value. All models included a fixed effect of the interquartile range of performance error as a covariate of no interest, and a random effect of participants on the intercept. Total intracranial volume was estimated from the T1-weighted MP2RAGE images using the mri_segstats–etiv-only procedure in FreeSurfer v6.0.0. <bold>Table B. Bayes Factors for the inclusion of fixed effects in the linear mixed effects model predicting prior weighting.</bold> P(incl): prior inclusion probability, i.e. the summed prior probability of models that include the predictor. A priori, all possible restrictions of the full model were deemed to be equally likely (i.e., a uniform prior was assigned to the model space). Thus, P(incl) reflects the proportion of alternative models that included the predictor. P(incl|data): posterior inclusion probability, i.e. the summed posterior probability of models that include the predictor. P(excl|data): posterior exclusion probability, i.e. the summed posterior probability of models that exclude the predictor. BF<sub>inclusion</sub>: Inclusion Bayes Factor, i.e. the change from prior to posterior inclusion odds. This indicates how much more likely the data are under models that include the predictor, compared to models that exclude the predictor. This analysis was performed using “matched” models, which means that (i) models were not permitted to include an interaction effect without its constituent main effects, and (ii) inclusion probabilities for an interaction effect were based only on the subset of models that contained (at least) the constituent main effects of the interaction. All models included a fixed effect of the interquartile range of performance error as a covariate of no interest, and a random effect of participants on the intercept.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s007.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s008" position="float" content-type="local-data">
                <label>S3 Text</label>
                <caption>
                  <title>Decomposing drug effects on prior weighting: Plausible values analysis.</title>
                  <p><bold>Fig A. Decomposing the noradrenergic effects on prior weighting using a plausible values analysis approach.</bold> (A-B) Distributions of plausible correlations between the drug effect on prior weighting and the estimated drug effect on the standard deviation of the prior (A) or sensory evidence (B). (C) Distribution of the difference between the plausible correlations.</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s008.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s009" position="float" content-type="local-data">
                <label>S4 Text</label>
                <caption>
                  <title>Effects of effort and reward on task performance and prior weighting.</title>
                  <p><bold>Fig A. Task accuracy (median force error) plotted as a function of effort, reward, group, and drug.</bold> Dots represent individual participants, and boxplots represent the marginal distribution for a given condition. For the Parkinson’s disease group, the grey lines indicate within-subject change in median force error from placebo to atomoxetine. Box-plot elements: centre line, median; box limits, first and third quartiles; whiskers, most extreme observations within 1.5 × interquartile range from the box limits. <bold>Fig B. Task variability (interquartile range of force error) plotted as a function of effort, reward, group, and drug.</bold> Dots represent individual participants, and boxplots represent the marginal distribution for a given condition. For the Parkinson’s disease group, the grey lines indicate within-subject change in the interquartile range of force error from placebo to atomoxetine. Box-plot elements: centre line, median; box limits, first and third quartiles; whiskers, most extreme observations within 1.5 × interquartile range from the box limits. <bold>Fig C. Prior weighting plotted as a function of effort, reward, group, and drug.</bold> Dots represent individual participants, and boxplots represent the marginal distribution for a given condition. For the Parkinson’s disease group, the grey lines indicate within-subject change in prior weighting from placebo to atomoxetine. Box-plot elements: centre line, median; box limits, first and third quartiles; whiskers, most extreme observations within 1.5 × interquartile range from the box limits. <bold>Table A. Estimated marginal means of median force error by group, effort, and reward. Table B. Estimated marginal means of median force error by drug, effort, and reward. Table C. Estimated marginal means of interquartile range of force error by group, effort, and reward. Table D. Estimated marginal means of interquartile range of force error by drug, effort, and reward. Table E. Estimated marginal means of prior weighting by group, effort, and reward. Table F. Estimated marginal means of prior weighting by drug, effort, and reward.</bold></p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s009.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s010" position="float" content-type="local-data">
                <label>S5 Text</label>
                <caption>
                  <title>Parameter recovery of prior weighting.</title>
                  <p><bold>Fig A. Parameter recovery of prior weighting.</bold> (A) Data-generating prior weighting plotted against the estimated (i.e., recovered) prior weighting. The diagonal (identity) line represents perfect parameter recovery. For a given data-generating prior weighting value, the dot represents the median of the prior weighting estimates across 2000 simulations of estimation errors; the vertical error bars represent the 95% quantile intervals of the prior weighting estimates. The inset histogram illustrates the distribution of the difference between the median estimated prior weighting and data-generating prior weighting. (B, C) Examples of data simulations for a relatively low data-generating value of prior weighting (B; orange dot and error bar in A) and a relatively high data-generating value of prior weighting (C; green dot in A).</p>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s010.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pcbi.1010079.s011" position="float" content-type="local-data">
                <label>S6 Text</label>
                <caption>
                  <title>Details of statistical software.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pcbi.1010079.s011.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank the volunteers for their participation, staff at the Wolfson Brain Imaging Centre and National Institute for Health and Care Research (NIHR) Cambridge Clinical Research Facility for their help with data collection, and members of the Cambridge Centre for Frontotemporal Dementia and Related Disorders for valuable suggestions and discussions.</p>
              <p>The views expressed are those of the authors and not necessarily those of the National Institute for Health and Care Research or the Department of Health and Social Care.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pcbi.1010079.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>den Brok</surname><given-names>MGHE</given-names></name>, <name><surname>van Dalen</surname><given-names>JW</given-names></name>, <name><surname>van Gool</surname><given-names>WA</given-names></name>, <name><surname>van Charante</surname><given-names>EPM</given-names></name>, <name><surname>de Bie</surname><given-names>RMA</given-names></name>, <name><surname>Richard</surname><given-names>E</given-names></name>. <article-title>Apathy in Parkinson’s disease: A systematic review and meta-analysis</article-title>. <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>: <fpage>759</fpage>–<lpage>769</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.26208</pub-id>
<?supplied-pmid 25787145?><pub-id pub-id-type="pmid">25787145</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Lanctôt</surname><given-names>KL</given-names></name>, <name><surname>Agüera-Ortiz</surname><given-names>L</given-names></name>, <name><surname>Brodaty</surname><given-names>H</given-names></name>, <name><surname>Francis</surname><given-names>PT</given-names></name>, <name><surname>Geda</surname><given-names>YE</given-names></name>, <name><surname>Ismail</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Apathy associated with neurocognitive disorders: Recent progress and future directions</article-title>. <source>Alzheimers Dement</source>. <year>2017</year>;<volume>13</volume>: <fpage>84</fpage>–<lpage>100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jalz.2016.05.008</pub-id>
<?supplied-pmid 27362291?><pub-id pub-id-type="pmid">27362291</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Lansdall</surname><given-names>CJ</given-names></name>, <name><surname>Coyle-Gilchrist</surname><given-names>ITS</given-names></name>, <name><surname>Vázquez Rodríguez</surname><given-names>P</given-names></name>, <name><surname>Wilcox</surname><given-names>A</given-names></name>, <name><surname>Wehmann</surname><given-names>E</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <etal>et al</etal>. <article-title>Prognostic importance of apathy in syndromes associated with frontotemporal lobar degeneration</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>: <fpage>e1547</fpage>–<lpage>e1557</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1212/WNL.0000000000007249</pub-id>
<?supplied-pmid 30842292?><pub-id pub-id-type="pmid">30842292</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Ang</surname><given-names>Y-S</given-names></name>, <name><surname>Lockwood</surname><given-names>P</given-names></name>, <name><surname>Apps</surname><given-names>MAJ</given-names></name>, <name><surname>Muhammed</surname><given-names>K</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <article-title>Distinct Subtypes of Apathy Revealed by the Apathy Motivation Index</article-title>. <name><surname>Gulinello</surname><given-names>M</given-names></name>, editor. <source>PLOS ONE</source>. <year>2017</year>;<volume>12</volume>: <fpage>e0169938</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0169938</pub-id><?supplied-pmid 28076387?><pub-id pub-id-type="pmid">28076387</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Petitet</surname><given-names>P</given-names></name>, <name><surname>Scholl</surname><given-names>J</given-names></name>, <name><surname>Attaallah</surname><given-names>B</given-names></name>, <name><surname>Drew</surname><given-names>D</given-names></name>, <name><surname>Manohar</surname><given-names>S</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <article-title>The relationship between apathy and impulsivity in large population samples</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>: <fpage>4830</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-021-84364-w</pub-id><?supplied-pmid 33649399?><pub-id pub-id-type="pmid">33649399</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Levy</surname><given-names>R</given-names></name>, <name><surname>Dubois</surname><given-names>B</given-names></name>. <article-title>Apathy and the Functional Anatomy of the Prefrontal Cortex–Basal Ganglia Circuits</article-title>. <source>Cereb Cortex</source>. <year>2005</year>;<volume>16</volume>: <fpage>916</fpage>–<lpage>928</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cercor/bhj043</pub-id>
<?supplied-pmid 16207933?><pub-id pub-id-type="pmid">16207933</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Marin</surname><given-names>RS</given-names></name>. <article-title>Apathy: a neuropsychiatric syndrome</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>1991</year>;<volume>3</volume>: <fpage>243</fpage>–<lpage>254</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1176/jnp.3.3.243</pub-id>
<?supplied-pmid 1821241?><pub-id pub-id-type="pmid">1821241</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Passamonti</surname><given-names>L</given-names></name>, <name><surname>Lansdall</surname><given-names>CJ</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration.</article-title><source>Curr Opin Behav Sci</source>. <year>2018</year>;<volume>22</volume>: <fpage>14</fpage>–<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cobeha.2017.12.015</pub-id>
<?supplied-pmid 31032387?><pub-id pub-id-type="pmid">31032387</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref009">
                <label>9</label>
                <mixed-citation publication-type="book"><name><surname>Chong</surname><given-names>TT-J</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <part-title>Chapter 17—The role of dopamine in the pathophysiology and treatment of apathy</part-title>. In: <name><surname>Studer</surname><given-names>B</given-names></name>, <name><surname>Knecht</surname><given-names>S</given-names></name>, editors. <source>Progress in Brain Research</source>. <publisher-name>Elsevier</publisher-name>; <year>2016</year>. pp. <fpage>389</fpage>–<lpage>426</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/bs.pbr.2016.05.007</pub-id>
<?supplied-pmid 27926449?></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Poewe</surname><given-names>W</given-names></name>, <name><surname>Seppi</surname><given-names>K</given-names></name>, <name><surname>Tanner</surname><given-names>CM</given-names></name>, <name><surname>Halliday</surname><given-names>GM</given-names></name>, <name><surname>Brundin</surname><given-names>P</given-names></name>, <name><surname>Volkmann</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Parkinson disease.</article-title><source>Nat Rev Dis Primer</source>. <year>2017</year>;<volume>3</volume>: <fpage>1</fpage>–<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id>
<?supplied-pmid 28332488?><pub-id pub-id-type="pmid">28332488</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Niv</surname><given-names>Y</given-names></name>, <name><surname>Daw</surname><given-names>ND</given-names></name>, <name><surname>Joel</surname><given-names>D</given-names></name>, <name><surname>Dayan</surname><given-names>P</given-names></name>. <article-title>Tonic dopamine: opportunity costs and the control of response vigor</article-title>. <source>Psychopharmacology (Berl).</source><year>2007</year>;<volume>191</volume>: <fpage>507</fpage>–<lpage>520</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00213-006-0502-4</pub-id>
<?supplied-pmid 17031711?><pub-id pub-id-type="pmid">17031711</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Schultz</surname><given-names>W</given-names></name>, <name><surname>Dayan</surname><given-names>P</given-names></name>, <name><surname>Montague</surname><given-names>PR</given-names></name>. <article-title>A Neural Substrate of Prediction and Reward</article-title>. <source>Science</source>. <year>1997</year>;<volume>275</volume>: <fpage>1593</fpage>–<lpage>1599</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.275.5306.1593</pub-id>
<?supplied-pmid 9054347?><pub-id pub-id-type="pmid">9054347</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Chong</surname><given-names>TT-J</given-names></name>, <name><surname>Bonnelle</surname><given-names>V</given-names></name>, <name><surname>Manohar</surname><given-names>S</given-names></name>, <name><surname>Veromann</surname><given-names>K-R</given-names></name>, <name><surname>Muhammed</surname><given-names>K</given-names></name>, <name><surname>Tofaris</surname><given-names>GK</given-names></name>, <etal>et al</etal>. <article-title>Dopamine enhances willingness to exert effort for reward in Parkinson’s disease</article-title>. <source>Cortex</source>. <year>2015</year>;<volume>69</volume>: <fpage>40</fpage>–<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cortex.2015.04.003</pub-id>
<?supplied-pmid 25967086?><pub-id pub-id-type="pmid">25967086</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Le Bouc</surname><given-names>R</given-names></name>, <name><surname>Rigoux</surname><given-names>L</given-names></name>, <name><surname>Schmidt</surname><given-names>L</given-names></name>, <name><surname>Degos</surname><given-names>B</given-names></name>, <name><surname>Welter</surname><given-names>M-L</given-names></name>, <name><surname>Vidailhet</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Computational Dissection of Dopamine Motor and Motivational Functions in Humans</article-title>. <source>J Neurosci</source>. <year>2016</year>;<volume>36</volume>: <fpage>6623</fpage>–<lpage>6633</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3078-15.2016</pub-id>
<?supplied-pmid 27335396?><pub-id pub-id-type="pmid">27335396</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Muhammed</surname><given-names>K</given-names></name>, <name><surname>Manohar</surname><given-names>S</given-names></name>, <name><surname>Yehuda</surname><given-names>MB</given-names></name>, <name><surname>Chong</surname><given-names>TT-J</given-names></name>, <name><surname>Tofaris</surname><given-names>G</given-names></name>, <name><surname>Lennox</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Reward sensitivity deficits modulated by dopamine are associated with apathy in Parkinson’s disease</article-title>. <source>Brain</source>. <year>2016</year>;<volume>139</volume>: <fpage>2706</fpage>–<lpage>2721</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/aww188</pub-id>
<?supplied-pmid 27452600?><pub-id pub-id-type="pmid">27452600</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Lansdall</surname><given-names>CJ</given-names></name>, <name><surname>Coyle-Gilchrist</surname><given-names>ITS</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <name><surname>Rodríguez</surname><given-names>PV</given-names></name>, <name><surname>Wilcox</surname><given-names>A</given-names></name>, <name><surname>Wehmann</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Apathy and impulsivity in frontotemporal lobar degeneration syndromes</article-title>. <source>Brain</source>. <year>2017</year>;<volume>140</volume>: <fpage>1792</fpage>–<lpage>1807</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awx101</pub-id>
<?supplied-pmid 28486594?><pub-id pub-id-type="pmid">28486594</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Murley</surname><given-names>AG</given-names></name>, <name><surname>Coyle-Gilchrist</surname><given-names>I</given-names></name>, <name><surname>Rouse</surname><given-names>MA</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Wiggins</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Redefining the multidimensional clinical phenotypes of frontotemporal lobar degeneration syndromes</article-title>. <source>Brain</source>. <year>2020</year>;<volume>143</volume>: <fpage>1555</fpage>–<lpage>1571</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awaa097</pub-id>
<?supplied-pmid 32438414?><pub-id pub-id-type="pmid">32438414</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>BM</given-names></name>, <name><surname>Eisinger</surname><given-names>RS</given-names></name>, <name><surname>Burns</surname><given-names>MR</given-names></name>, <name><surname>Lopes</surname><given-names>J</given-names></name>, <name><surname>Okun</surname><given-names>MS</given-names></name>, <name><surname>Gunduz</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Co-occurrence of apathy and impulse control disorders in Parkinson disease</article-title>. <source>Neurology</source>. <year>2020</year>;<volume>95</volume>: <fpage>e2769</fpage>–<lpage>e2780</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1212/WNL.0000000000010965</pub-id>
<?supplied-pmid 33004605?><pub-id pub-id-type="pmid">33004605</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Sinha</surname><given-names>N</given-names></name>, <name><surname>Manohar</surname><given-names>S</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <article-title>Impulsivity and apathy in Parkinson’s disease</article-title>. <source>J Neuropsychol.</source><year>2013</year>;<volume>7</volume>: <fpage>255</fpage>–<lpage>283</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/jnp.12013</pub-id>
<?supplied-pmid 23621377?><pub-id pub-id-type="pmid">23621377</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Zoon</surname><given-names>TJC</given-names></name>, <name><surname>Rooijen</surname><given-names>G</given-names></name>, <name><surname>Balm</surname><given-names>GMFC</given-names></name>, <name><surname>Bergfeld</surname><given-names>IO</given-names></name>, <name><surname>Daams</surname><given-names>JG</given-names></name>, <name><surname>Krack</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: A Meta-Analysis</article-title>. <source>Mov Disord</source>. <year>2021</year>;<volume>36</volume>: <fpage>317</fpage>–<lpage>326</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.28390</pub-id>
<?supplied-pmid 33331023?><pub-id pub-id-type="pmid">33331023</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Bouret</surname><given-names>S</given-names></name>, <name><surname>Richmond</surname><given-names>BJ</given-names></name>. <article-title>Sensitivity of Locus Ceruleus Neurons to Reward Value for Goal-Directed Actions</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>: <fpage>4005</fpage>–<lpage>4014</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4553-14.2015</pub-id>
<?supplied-pmid 25740528?><pub-id pub-id-type="pmid">25740528</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Jahn</surname><given-names>CI</given-names></name>, <name><surname>Varazzani</surname><given-names>C</given-names></name>, <name><surname>Sallet</surname><given-names>J</given-names></name>, <name><surname>Walton</surname><given-names>ME</given-names></name>, <name><surname>Bouret</surname><given-names>S</given-names></name>. <article-title>Noradrenergic But Not Dopaminergic Neurons Signal Task State Changes and Predict Reengagement After a Failure</article-title>. <source>Cereb Cortex</source>. <year>2020</year> [cited 17 May 2020]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cercor/bhaa089</pub-id>
<?supplied-pmid 32390051?><pub-id pub-id-type="pmid">32390051</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Varazzani</surname><given-names>C</given-names></name>, <name><surname>San-Galli</surname><given-names>A</given-names></name>, <name><surname>Gilardeau</surname><given-names>S</given-names></name>, <name><surname>Bouret</surname><given-names>S</given-names></name>. <article-title>Noradrenaline and Dopamine Neurons in the Reward/Effort Trade-Off: A Direct Electrophysiological Comparison in Behaving Monkeys</article-title>. <source>J Neurosci</source>. <year>2015</year>;<volume>35</volume>: <fpage>7866</fpage>–<lpage>7877</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0454-15.2015</pub-id>
<?supplied-pmid 25995472?><pub-id pub-id-type="pmid">25995472</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>RY</given-names></name>, <name><surname>Bloom</surname><given-names>FE</given-names></name>. <article-title>Central Catecholamine Neuron Systems: Anatomy and Physiology of the Norepinephrine and Epinephrine Systems</article-title>. <source>Annu Rev Neurosci</source>. <year>1979</year>;<volume>2</volume>: <fpage>113</fpage>–<lpage>168</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.ne.02.030179.000553</pub-id>
<?supplied-pmid 231924?><pub-id pub-id-type="pmid">231924</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Szabadi</surname><given-names>E.</given-names></name><article-title>Functional neuroanatomy of the central noradrenergic system</article-title>. <source>J Psychopharmacol (Oxf).</source><year>2013</year>;<volume>27</volume>: <fpage>659</fpage>–<lpage>693</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0269881113490326</pub-id>
<?supplied-pmid 23761387?><pub-id pub-id-type="pmid">23761387</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Hawkes</surname><given-names>CH</given-names></name>, <name><surname>Del Tredici</surname><given-names>K</given-names></name>, <name><surname>Braak</surname><given-names>H</given-names></name>. <article-title>A timeline for Parkinson’s disease</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2010</year>;<volume>16</volume>: <fpage>79</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.parkreldis.2009.08.007</pub-id>
<?supplied-pmid 19846332?><pub-id pub-id-type="pmid">19846332</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Surmeier</surname><given-names>DJ</given-names></name>, <name><surname>Obeso</surname><given-names>JA</given-names></name>, <name><surname>Halliday</surname><given-names>GM</given-names></name>. <article-title>Selective neuronal vulnerability in Parkinson disease</article-title>. <source>Nat Rev Neurosci</source>. <year>2017</year>;<volume>18</volume>: <fpage>101</fpage>–<lpage>113</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrn.2016.178</pub-id>
<?supplied-pmid 28104909?><pub-id pub-id-type="pmid">28104909</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Zarow</surname><given-names>C</given-names></name>, <name><surname>Lyness</surname><given-names>SA</given-names></name>, <name><surname>Mortimer</surname><given-names>JA</given-names></name>, <name><surname>Chui</surname><given-names>HC</given-names></name>. <article-title>Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases</article-title>. <source>Arch Neurol</source>. <year>2003</year>;<volume>60</volume>: <fpage>337</fpage>–<lpage>341</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/archneur.60.3.337</pub-id>
<?supplied-pmid 12633144?><pub-id pub-id-type="pmid">12633144</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Kehagia</surname><given-names>AA</given-names></name>, <name><surname>Housden</surname><given-names>CR</given-names></name>, <name><surname>Regenthal</surname><given-names>R</given-names></name>, <name><surname>Barker</surname><given-names>RA</given-names></name>, <name><surname>Müller</surname><given-names>U</given-names></name>, <name><surname>Rowe</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Targeting impulsivity in Parkinson’s disease using atomoxetine</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>: <fpage>1986</fpage>–<lpage>1997</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awu117</pub-id>
<?supplied-pmid 24893708?><pub-id pub-id-type="pmid">24893708</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Lewis</surname><given-names>SJG</given-names></name>, <name><surname>Slabosz</surname><given-names>A</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <name><surname>Barker</surname><given-names>RA</given-names></name>, <name><surname>Owen</surname><given-names>AM</given-names></name>. <article-title>Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson’s disease</article-title>. <source>Neuropsychologia</source>. <year>2005</year>;<volume>43</volume>: <fpage>823</fpage>–<lpage>832</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2004.10.001</pub-id>
<?supplied-pmid 15716155?><pub-id pub-id-type="pmid">15716155</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Loued-Khenissi</surname><given-names>L</given-names></name>, <name><surname>Preuschoff</surname><given-names>K</given-names></name>. <article-title>Apathy and noradrenaline: silent partners to mild cognitive impairment in Parkinsonʼs disease?</article-title><source>Curr Opin Neurol</source>. <year>2015</year>;<volume>28</volume>: <fpage>344</fpage>–<lpage>350</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/WCO.0000000000000218</pub-id>
<?supplied-pmid 26110801?><pub-id pub-id-type="pmid">26110801</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Tredici</surname><given-names>KD</given-names></name>, <name><surname>Braak</surname><given-names>H</given-names></name>. <article-title>Dysfunction of the locus coeruleus–norepinephrine system and related circuitry in Parkinson’s disease-related dementia</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2013</year>;<volume>84</volume>: <fpage>774</fpage>–<lpage>783</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/jnnp-2011-301817</pub-id>
<?supplied-pmid 23064099?><pub-id pub-id-type="pmid">23064099</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Bouret</surname><given-names>S</given-names></name>, <name><surname>Sara</surname><given-names>SJ</given-names></name>. <article-title>Network reset: a simplified overarching theory of locus coeruleus noradrenaline function</article-title>. <source>Trends Neurosci</source>. <year>2005</year>;<volume>28</volume>: <fpage>574</fpage>–<lpage>582</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tins.2005.09.002</pub-id>
<?supplied-pmid 16165227?><pub-id pub-id-type="pmid">16165227</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Dayan</surname><given-names>P</given-names></name>, <name><surname>Yu</surname><given-names>AJ</given-names></name>. <article-title>Phasic norepinephrine: A neural interrupt signal for unexpected events</article-title>. <source>Netw Comput Neural Syst</source>. <year>2006</year>;<volume>17</volume>: <fpage>335</fpage>–<lpage>350</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/09548980601004024</pub-id>
<?supplied-pmid 17162459?><pub-id pub-id-type="pmid">17162459</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Aston-Jones</surname><given-names>G</given-names></name>, <name><surname>Cohen</surname><given-names>JD</given-names></name>. <article-title>An integrative theory of locus coeruleus-norepinephrine function: Adaptive Gain and Optimal Performance</article-title>. <source>Annu Rev Neurosci</source>. <year>2005</year>;<volume>28</volume>: <fpage>403</fpage>–<lpage>450</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.neuro.28.061604.135709</pub-id>
<?supplied-pmid 16022602?><pub-id pub-id-type="pmid">16022602</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Yu</surname><given-names>AJ</given-names></name>, <name><surname>Dayan</surname><given-names>P</given-names></name>. <article-title>Uncertainty, Neuromodulation, and Attention</article-title>. <source>Neuron</source>. <year>2005</year>;<volume>46</volume>: <fpage>681</fpage>–<lpage>692</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuron.2005.04.026</pub-id>
<?supplied-pmid 15944135?><pub-id pub-id-type="pmid">15944135</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Joshi</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Kalwani</surname><given-names>RM</given-names></name>, <name><surname>Gold</surname><given-names>JI</given-names></name>. <article-title>Relationships between Pupil Diameter and Neuronal Activity in the Locus Coeruleus, Colliculi, and Cingulate Cortex</article-title>. <source>Neuron</source>. <year>2016</year>;<volume>89</volume>: <fpage>221</fpage>–<lpage>234</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuron.2015.11.028</pub-id>
<?supplied-pmid 26711118?><pub-id pub-id-type="pmid">26711118</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Jepma</surname><given-names>M</given-names></name>, <name><surname>Murphy</surname><given-names>PR</given-names></name>, <name><surname>Nassar</surname><given-names>MR</given-names></name>, <name><surname>Rangel-Gomez</surname><given-names>M</given-names></name>, <name><surname>Meeter</surname><given-names>M</given-names></name>, <name><surname>Nieuwenhuis</surname><given-names>S</given-names></name>. <article-title>Catecholaminergic Regulation of Learning Rate in a Dynamic Environment.</article-title><source>PLOS Comput Biol.</source><year>2016</year>;<volume>12</volume>: <fpage>e1005171</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005171</pub-id><?supplied-pmid 27792728?><pub-id pub-id-type="pmid">27792728</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Krishnamurthy</surname><given-names>K</given-names></name>, <name><surname>Nassar</surname><given-names>MR</given-names></name>, <name><surname>Sarode</surname><given-names>S</given-names></name>, <name><surname>Gold</surname><given-names>JI</given-names></name>. <article-title>Arousal-related adjustments of perceptual biases optimize perception in dynamic environments</article-title>. <source>Nat Hum Behav</source>. <year>2017</year>;<volume>1</volume>: <fpage>1</fpage>–<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41562-017-0107</pub-id>
<?supplied-pmid 29034334?><pub-id pub-id-type="pmid">29034334</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Lawson</surname><given-names>RP</given-names></name>, <name><surname>Bisby</surname><given-names>J</given-names></name>, <name><surname>Nord</surname><given-names>CL</given-names></name>, <name><surname>Burgess</surname><given-names>N</given-names></name>, <name><surname>Rees</surname><given-names>G</given-names></name>. <article-title>The Computational, Pharmacological, and Physiological Determinants of Sensory Learning under Uncertainty</article-title>. <source>Curr Biol</source>. <year>2021</year>;<volume>31</volume>: <fpage>163</fpage>–<lpage>172.e4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cub.2020.10.043</pub-id>
<?supplied-pmid 33188745?><pub-id pub-id-type="pmid">33188745</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Muller</surname><given-names>TH</given-names></name>, <name><surname>Mars</surname><given-names>RB</given-names></name>, <name><surname>Behrens</surname><given-names>TE</given-names></name>, <name><surname>O’Reilly</surname><given-names>JX</given-names></name>. <article-title>Control of entropy in neural models of environmental state</article-title>. <name><surname>Donner</surname><given-names>TH</given-names></name>, <name><surname>Frank</surname><given-names>MJ</given-names></name>, <name><surname>Gershman</surname><given-names>SJ</given-names></name>, <name><surname>Meyniel</surname><given-names>F</given-names></name>, editors. <source>eLife</source>. <year>2019</year>;<volume>8</volume>: <fpage>e39404</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7554/eLife.39404</pub-id><?supplied-pmid 30816090?><pub-id pub-id-type="pmid">30816090</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Nassar</surname><given-names>MR</given-names></name>, <name><surname>Rumsey</surname><given-names>KM</given-names></name>, <name><surname>Wilson</surname><given-names>RC</given-names></name>, <name><surname>Parikh</surname><given-names>K</given-names></name>, <name><surname>Heasly</surname><given-names>B</given-names></name>, <name><surname>Gold</surname><given-names>JI</given-names></name>. <article-title>Rational regulation of learning dynamics by pupil-linked arousal systems</article-title>. <source>Nat Neurosci</source>. <year>2012</year>;<volume>15</volume>: <fpage>1040</fpage>–<lpage>1046</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn.3130</pub-id>
<?supplied-pmid 22660479?><pub-id pub-id-type="pmid">22660479</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Hezemans</surname><given-names>FH</given-names></name>, <name><surname>Wolpe</surname><given-names>N</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>Apathy is associated with reduced precision of prior beliefs about action outcomes</article-title>. <source>J Exp Psychol Gen</source>. <year>2020</year> [cited 17 May 2020]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1037/xge0000739</pub-id>
<?supplied-pmid 32039624?><pub-id pub-id-type="pmid">32039624</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>The free-energy principle: a unified brain theory?</article-title><source>Nat Rev Neurosci.</source><year>2010</year>;<volume>11</volume>: <fpage>127</fpage>–<lpage>138</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrn2787</pub-id>
<?supplied-pmid 20068583?><pub-id pub-id-type="pmid">20068583</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Friston</surname><given-names>KJ</given-names></name>, <name><surname>FitzGerald</surname><given-names>T</given-names></name>, <name><surname>Rigoli</surname><given-names>F</given-names></name>, <name><surname>Schwartenbeck</surname><given-names>P</given-names></name>, <name><surname>Pezzulo</surname><given-names>G</given-names></name>. <article-title>Active Inference: A Process Theory.</article-title><source>Neural Comput</source>. <year>2016</year>;<volume>29</volume>: <fpage>1</fpage>–<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1162/NECO_a_00912</pub-id>
<?supplied-pmid 27870614?><pub-id pub-id-type="pmid">27870614</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref046">
                <label>46</label>
                <mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>RA</given-names></name>, <name><surname>Shipp</surname><given-names>S</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>Predictions not commands: active inference in the motor system</article-title>. <source>Brain Struct Funct</source>. <year>2013</year>;<volume>218</volume>: <fpage>611</fpage>–<lpage>643</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00429-012-0475-5</pub-id>
<?supplied-pmid 23129312?><pub-id pub-id-type="pmid">23129312</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref047">
                <label>47</label>
                <mixed-citation publication-type="journal"><name><surname>Friston</surname><given-names>KJ</given-names></name>, <name><surname>Daunizeau</surname><given-names>J</given-names></name>, <name><surname>Kilner</surname><given-names>J</given-names></name>, <name><surname>Kiebel</surname><given-names>SJ</given-names></name>. <article-title>Action and behavior: a free-energy formulation</article-title>. <source>Biol Cybern.</source><year>2010</year>;<volume>102</volume>: <fpage>227</fpage>–<lpage>260</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00422-010-0364-z</pub-id>
<?supplied-pmid 20148260?><pub-id pub-id-type="pmid">20148260</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref048">
                <label>48</label>
                <mixed-citation publication-type="journal"><name><surname>Wiese</surname><given-names>W.</given-names></name><article-title>Action Is Enabled by Systematic Misrepresentations</article-title>. <source>Erkenntnis</source>. <year>2017</year>;<volume>82</volume>: <fpage>1233</fpage>–<lpage>1252</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s10670-016-9867-x</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref049">
                <label>49</label>
                <mixed-citation publication-type="journal"><name><surname>Friston</surname><given-names>KJ</given-names></name>, <name><surname>Schwartenbeck</surname><given-names>P</given-names></name>, <name><surname>FitzGerald</surname><given-names>T</given-names></name>, <name><surname>Moutoussis</surname><given-names>M</given-names></name>, <name><surname>Behrens</surname><given-names>T</given-names></name>, <name><surname>Dolan</surname><given-names>RJ</given-names></name>. <article-title>The anatomy of choice: dopamine and decision-making.</article-title><source>Philos Trans R Soc B Biol Sci</source>. <year>2014</year>;<volume>369</volume>: <fpage>20130481</fpage>–<lpage>20130481</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rstb.2013.0481</pub-id>
<?supplied-pmid 25267823?><pub-id pub-id-type="pmid">25267823</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref050">
                <label>50</label>
                <mixed-citation publication-type="journal"><name><surname>Friston</surname><given-names>KJ</given-names></name>, <name><surname>Shiner</surname><given-names>T</given-names></name>, <name><surname>FitzGerald</surname><given-names>T</given-names></name>, <name><surname>Galea</surname><given-names>JM</given-names></name>, <name><surname>Adams</surname><given-names>RA</given-names></name>, <name><surname>Brown</surname><given-names>HR</given-names></name>, <etal>et al</etal>. <article-title>Dopamine, Affordance and Active Inference</article-title>. <source>PLOS Comput Biol.</source><year>2012</year>;<volume>8</volume>: <fpage>e1002327</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1002327</pub-id><?supplied-pmid 22241972?><pub-id pub-id-type="pmid">22241972</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref051">
                <label>51</label>
                <mixed-citation publication-type="journal"><name><surname>Parr</surname><given-names>T</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>Uncertainty, epistemics and active inference</article-title>. <source>J R Soc Interface</source>. <year>2017</year>;<volume>14</volume>: <fpage>20170376</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1098/rsif.2017.0376</pub-id><?supplied-pmid 29167370?><pub-id pub-id-type="pmid">29167370</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref052">
                <label>52</label>
                <mixed-citation publication-type="journal"><name><surname>Sales</surname><given-names>AC</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>, <name><surname>Jones</surname><given-names>MW</given-names></name>, <name><surname>Pickering</surname><given-names>AE</given-names></name>, <name><surname>Moran</surname><given-names>RJ</given-names></name>. <article-title>Locus Coeruleus tracking of prediction errors optimises cognitive flexibility: An Active Inference model</article-title>. <name><surname>Gershman</surname><given-names>SJ</given-names></name> editor. <source>PLOS Comput Biol.</source>
<year>2019</year>;<volume>15</volume>: <fpage>e1006267</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1006267</pub-id>
<?supplied-pmid 30608922?><pub-id pub-id-type="pmid">30608922</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref053">
                <label>53</label>
                <mixed-citation publication-type="journal"><name><surname>Schwartenbeck</surname><given-names>P</given-names></name>, <name><surname>FitzGerald</surname><given-names>THB</given-names></name>, <name><surname>Mathys</surname><given-names>C</given-names></name>, <name><surname>Dolan</surname><given-names>R</given-names></name>, <name><surname>Friston</surname><given-names>K</given-names></name>. <article-title>The Dopaminergic Midbrain Encodes the Expected Certainty about Desired Outcomes</article-title>. <source>Cereb Cortex</source>. <year>2015</year>;<volume>25</volume>: <fpage>3434</fpage>–<lpage>3445</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cercor/bhu159</pub-id>
<?supplied-pmid 25056572?><pub-id pub-id-type="pmid">25056572</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref054">
                <label>54</label>
                <mixed-citation publication-type="journal"><name><surname>Cools</surname><given-names>R.</given-names></name><article-title>Chemistry of the Adaptive Mind: Lessons from Dopamine</article-title>. <source>Neuron</source>. <year>2019</year>;<volume>104</volume>: <fpage>113</fpage>–<lpage>131</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuron.2019.09.035</pub-id>
<?supplied-pmid 31600509?><pub-id pub-id-type="pmid">31600509</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref055">
                <label>55</label>
                <mixed-citation publication-type="journal"><name><surname>Holland</surname><given-names>N</given-names></name>, <name><surname>Robbins</surname><given-names>TW</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>The role of noradrenaline in cognition and cognitive disorders</article-title>. <source>Brain</source>. <year>2021</year> [cited 11 Mar 2021]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awab111</pub-id>
<?supplied-pmid 33725122?><pub-id pub-id-type="pmid">33725122</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref056">
                <label>56</label>
                <mixed-citation publication-type="journal"><name><surname>Robbins</surname><given-names>TW</given-names></name>, <name><surname>Arnsten</surname><given-names>AFT</given-names></name>. <article-title>The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation</article-title>. <source>Annu Rev Neurosci</source>. <year>2009</year>;<volume>32</volume>: <fpage>267</fpage>–<lpage>287</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.neuro.051508.135535</pub-id>
<?supplied-pmid 19555290?><pub-id pub-id-type="pmid">19555290</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref057">
                <label>57</label>
                <mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>R</given-names></name>, <name><surname>Rua</surname><given-names>C</given-names></name>, <name><surname>O’Callaghan</surname><given-names>C</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <name><surname>Hezemans</surname><given-names>FH</given-names></name>, <name><surname>Kaalund</surname><given-names>SS</given-names></name>, <etal>et al</etal>. <article-title>An in vivo probabilistic atlas of the human locus coeruleus at ultra-high field</article-title>. <source>NeuroImage</source>. <year>2021</year>;<volume>225</volume>: <fpage>117487</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117487</pub-id><?supplied-pmid 33164875?><pub-id pub-id-type="pmid">33164875</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref058">
                <label>58</label>
                <mixed-citation publication-type="journal"><name><surname>Tomlinson</surname><given-names>CL</given-names></name>, <name><surname>Stowe</surname><given-names>R</given-names></name>, <name><surname>Patel</surname><given-names>S</given-names></name>, <name><surname>Rick</surname><given-names>C</given-names></name>, <name><surname>Gray</surname><given-names>R</given-names></name>, <name><surname>Clarke</surname><given-names>CE</given-names></name>. <article-title>Systematic review of levodopa dose equivalency reporting in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>: <fpage>2649</fpage>–<lpage>2653</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.23429</pub-id>
<?supplied-pmid 21069833?><pub-id pub-id-type="pmid">21069833</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref059">
                <label>59</label>
                <mixed-citation publication-type="journal"><name><surname>Starkstein</surname><given-names>SE</given-names></name>, <name><surname>Mayberg</surname><given-names>HS</given-names></name>, <name><surname>Preziosi</surname><given-names>TJ</given-names></name>, <name><surname>Andrezejewski</surname><given-names>P</given-names></name>, <name><surname>Leiguarda</surname><given-names>R</given-names></name>, <name><surname>Robinson</surname><given-names>RG</given-names></name>. <article-title>Reliability, validity, and clinical correlates of apathy in Parkinson’s disease</article-title>. <source>J Neuropsychiatry Clin Neurosci</source>. <year>1992</year>;<volume>4</volume>: <fpage>134</fpage>–<lpage>139</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1176/jnp.4.2.134</pub-id>
<?supplied-pmid 1627973?><pub-id pub-id-type="pmid">1627973</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref060">
                <label>60</label>
                <mixed-citation publication-type="journal"><name><surname>Wolpe</surname><given-names>N</given-names></name>, <name><surname>Wolpert</surname><given-names>DM</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>Seeing what you want to see: priors for one’s own actions represent exaggerated expectations of success.</article-title><source>Front Behav Neurosci.</source><year>2014</year>;<fpage>8</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fnbeh.2014.00008</pub-id><?supplied-pmid 24478655?><pub-id pub-id-type="pmid">24478655</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref061">
                <label>61</label>
                <mixed-citation publication-type="journal"><name><surname>Kelly</surname><given-names>C</given-names></name>, <name><surname>Price</surname><given-names>TD</given-names></name>. <article-title>Correcting for Regression to the Mean in Behavior and Ecology</article-title>. <source>Am Nat</source>. <year>2005</year>;<volume>166</volume>: <fpage>700</fpage>–<lpage>707</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/497402</pub-id>
<?supplied-pmid 16475086?><pub-id pub-id-type="pmid">16475086</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref062">
                <label>62</label>
                <mixed-citation publication-type="journal"><name><surname>O’Callaghan</surname><given-names>C</given-names></name>, <name><surname>Hezemans</surname><given-names>FH</given-names></name>, <name><surname>Ye</surname><given-names>R</given-names></name>, <name><surname>Rua</surname><given-names>C</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <name><surname>Murley</surname><given-names>AG</given-names></name>, <etal>et al</etal>. <article-title>Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson’s disease</article-title>. <source>Brain</source>. <year>2021</year>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awab142</pub-id><?supplied-pmid 33783470?><pub-id pub-id-type="pmid">33783470</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref063">
                <label>63</label>
                <mixed-citation publication-type="journal"><name><surname>Rua</surname><given-names>C</given-names></name>, <name><surname>O’Callaghan</surname><given-names>C</given-names></name>, <name><surname>Ye</surname><given-names>R</given-names></name>, <name><surname>Hezemans</surname><given-names>FH</given-names></name>, <name><surname>Passamonti</surname><given-names>L</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>Substantia nigra ferric overload and neuromelanin loss in Parkinson’s disease measured with 7T MRI.</article-title><source>Neurology</source>; <year>2021</year><month>Apr</month>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1101/2021.04.13.21255416</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref064">
                <label>64</label>
                <mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>DJ</given-names></name>, <name><surname>Curran</surname><given-names>PJ</given-names></name>. <article-title>Probing Interactions in Fixed and Multilevel Regression: Inferential and Graphical Techniques</article-title>. <source>Multivar Behav Res</source>. <year>2005</year>;<volume>40</volume>: <fpage>373</fpage>–<lpage>400</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1207/s15327906mbr4003_5</pub-id>
<?supplied-pmid 26794689?><pub-id pub-id-type="pmid">26794689</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref065">
                <label>65</label>
                <mixed-citation publication-type="journal"><name><surname>Macerollo</surname><given-names>A</given-names></name>, <name><surname>Chen</surname><given-names>J-C</given-names></name>, <name><surname>Korlipara</surname><given-names>P</given-names></name>, <name><surname>Foltynie</surname><given-names>T</given-names></name>, <name><surname>Rothwell</surname><given-names>J</given-names></name>, <name><surname>Edwards</surname><given-names>MJ</given-names></name>, <etal>et al</etal>. <article-title>Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson’s disease: A test of a new framework for bradykinesia</article-title>. <source>Mov Disord</source>. <year>2016</year>;<volume>31</volume>: <fpage>143</fpage>–<lpage>146</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.26493</pub-id>
<?supplied-pmid 26749120?><pub-id pub-id-type="pmid">26749120</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref066">
                <label>66</label>
                <mixed-citation publication-type="journal"><name><surname>Wolpe</surname><given-names>N</given-names></name>, <name><surname>Nombela</surname><given-names>C</given-names></name>, <name><surname>Ingram</surname><given-names>JN</given-names></name>, <name><surname>Wolpert</surname><given-names>DM</given-names></name>, <name><surname>Cam-CAN</surname></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>Sensory attenuation in Parkinson’s disease is related to disease severity and dopamine dose</article-title>. <source>Sci Rep.</source><year>2018</year>;<fpage>8</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-017-18329-3</pub-id><?supplied-pmid 29311689?><pub-id pub-id-type="pmid">29311689</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref067">
                <label>67</label>
                <mixed-citation publication-type="journal"><name><surname>Azulay</surname><given-names>J-P</given-names></name>, <name><surname>Mesure</surname><given-names>S</given-names></name>, <name><surname>Amblard</surname><given-names>B</given-names></name>, <name><surname>Blin</surname><given-names>O</given-names></name>, <name><surname>Sangla</surname><given-names>I</given-names></name>, <name><surname>Pouget</surname><given-names>J</given-names></name>. <article-title>Visual control of locomotion in Parkinson’s disease</article-title>. <source>Brain</source>. <year>1999</year>;<volume>122</volume>: <fpage>111</fpage>–<lpage>120</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/122.1.111</pub-id>
<?supplied-pmid 10050899?><pub-id pub-id-type="pmid">10050899</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref068">
                <label>68</label>
                <mixed-citation publication-type="journal"><name><surname>Klockgether</surname><given-names>T</given-names></name>, <name><surname>Dichgans</surname><given-names>J</given-names></name>. <article-title>Visual control of arm movement in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>1994</year>;<volume>9</volume>: <fpage>48</fpage>–<lpage>56</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.870090108</pub-id>
<?supplied-pmid 8139605?><pub-id pub-id-type="pmid">8139605</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref069">
                <label>69</label>
                <mixed-citation publication-type="journal"><name><surname>Thaut</surname><given-names>MH</given-names></name>, <name><surname>McIntosh</surname><given-names>GC</given-names></name>, <name><surname>Rice</surname><given-names>RR</given-names></name>, <name><surname>Miller</surname><given-names>RA</given-names></name>, <name><surname>Rathbun</surname><given-names>J</given-names></name>, <name><surname>Brault</surname><given-names>JM</given-names></name>. <article-title>Rhythmic auditory stimulation in gait training for Parkinson’s disease patients</article-title>. <source>Mov Disord</source>. <year>1996</year>;<volume>11</volume>: <fpage>193</fpage>–<lpage>200</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.870110213</pub-id>
<?supplied-pmid 8684391?><pub-id pub-id-type="pmid">8684391</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref070">
                <label>70</label>
                <mixed-citation publication-type="journal"><name><surname>Conte</surname><given-names>A</given-names></name>, <name><surname>Khan</surname><given-names>N</given-names></name>, <name><surname>Defazio</surname><given-names>G</given-names></name>, <name><surname>Rothwell</surname><given-names>JC</given-names></name>, <name><surname>Berardelli</surname><given-names>A</given-names></name>. <article-title>Pathophysiology of somatosensory abnormalities in Parkinson disease.</article-title><source>Nat Rev Neurol</source>. <year>2013</year>;<volume>9</volume>: <fpage>687</fpage>–<lpage>697</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrneurol.2013.224</pub-id>
<?supplied-pmid 24217516?><pub-id pub-id-type="pmid">24217516</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref071">
                <label>71</label>
                <mixed-citation publication-type="journal"><name><surname>Moran</surname><given-names>RJ</given-names></name>, <name><surname>Symmonds</surname><given-names>M</given-names></name>, <name><surname>Dolan</surname><given-names>RJ</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>The Brain Ages Optimally to Model Its Environment: Evidence from Sensory Learning over the Adult Lifespan</article-title>. <name><surname>Sporns</surname><given-names>O</given-names></name>, editor. <source>PLoS Comput Biol.</source><year>2014</year>;<volume>10</volume>: <fpage>e1003422</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1003422</pub-id><?supplied-pmid 24465195?><pub-id pub-id-type="pmid">24465195</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref072">
                <label>72</label>
                <mixed-citation publication-type="journal"><name><surname>Wolpe</surname><given-names>N</given-names></name>, <name><surname>Ingram</surname><given-names>JN</given-names></name>, <name><surname>Tsvetanov</surname><given-names>KA</given-names></name>, <name><surname>Geerligs</surname><given-names>L</given-names></name>, <name><surname>Kievit</surname><given-names>RA</given-names></name>, <name><surname>Henson</surname><given-names>RN</given-names></name>, <etal>et al</etal>. <article-title>Ageing increases reliance on sensorimotor prediction through structural and functional differences in frontostriatal circuits</article-title>. <source>Nat Commun.</source><year>2016</year>;<fpage>7</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ncomms13034</pub-id><?supplied-pmid 27694879?><pub-id pub-id-type="pmid">27694879</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref073">
                <label>73</label>
                <mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>Z</given-names></name>, <name><surname>Rae</surname><given-names>CL</given-names></name>, <name><surname>Nombela</surname><given-names>C</given-names></name>, <name><surname>Ham</surname><given-names>T</given-names></name>, <name><surname>Rittman</surname><given-names>T</given-names></name>, <name><surname>Jones</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <article-title>Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson’s disease with clinical and neuroimaging measures: Predicting Treatment Response in PD.</article-title><source>Hum Brain Mapp</source>. <year>2016</year>;<volume>37</volume>: <fpage>1026</fpage>–<lpage>1037</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/hbm.23087</pub-id>
<?supplied-pmid 26757216?><pub-id pub-id-type="pmid">26757216</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref074">
                <label>74</label>
                <mixed-citation publication-type="journal"><name><surname>Cools R</surname><given-names>D</given-names></name><article-title>’Esposito M. Inverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control</article-title>. <source>Biol Psychiatry</source>. <year>2011</year>;<volume>69</volume>: <fpage>e113</fpage>–<lpage>e125</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.03.028</pub-id>
<?supplied-pmid 21531388?><pub-id pub-id-type="pmid">21531388</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref075">
                <label>75</label>
                <mixed-citation publication-type="journal"><name><surname>Robbins</surname><given-names>TW</given-names></name>. <article-title>Chemical neuromodulation of frontal-executive functions in humans and other animals</article-title>. <source>Exp Brain Res</source>. <year>2000</year>;<volume>133</volume>: <fpage>130</fpage>–<lpage>138</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s002210000407</pub-id>
<?supplied-pmid 10933217?><pub-id pub-id-type="pmid">10933217</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref076">
                <label>76</label>
                <mixed-citation publication-type="journal"><name><surname>Meder</surname><given-names>D</given-names></name>, <name><surname>Herz</surname><given-names>DM</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>, <name><surname>Lehéricy</surname><given-names>S</given-names></name>, <name><surname>Siebner</surname><given-names>HR</given-names></name>. <article-title>The role of dopamine in the brain—lessons learned from Parkinson’s disease</article-title>. <source>NeuroImage.</source><year>2019</year>;<volume>190</volume>: <fpage>79</fpage>–<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.11.021</pub-id>
<?supplied-pmid 30465864?><pub-id pub-id-type="pmid">30465864</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref077">
                <label>77</label>
                <mixed-citation publication-type="journal"><name><surname>Gilzenrat</surname><given-names>MS</given-names></name>, <name><surname>Nieuwenhuis</surname><given-names>S</given-names></name>, <name><surname>Jepma</surname><given-names>M</given-names></name>, <name><surname>Cohen</surname><given-names>JD</given-names></name>. <article-title>Pupil diameter tracks changes in control state predicted by the adaptive gain theory of locus coeruleus function</article-title>. <source>Cogn Affect Behav Neurosci</source>. <year>2010</year>;<volume>10</volume>: <fpage>252</fpage>–<lpage>269</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/CABN.10.2.252</pub-id>
<?supplied-pmid 20498349?><pub-id pub-id-type="pmid">20498349</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref078">
                <label>78</label>
                <mixed-citation publication-type="journal"><name><surname>Jepma</surname><given-names>M</given-names></name>, <name><surname>Nieuwenhuis</surname><given-names>S</given-names></name>. <article-title>Pupil Diameter Predicts Changes in the Exploration–Exploitation Trade-off: Evidence for the Adaptive Gain Theory.</article-title><source>J Cogn Neurosci.</source><year>2011</year>;<volume>23</volume>: <fpage>1587</fpage>–<lpage>1596</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1162/jocn.2010.21548</pub-id>
<?supplied-pmid 20666595?><pub-id pub-id-type="pmid">20666595</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref079">
                <label>79</label>
                <mixed-citation publication-type="journal"><name><surname>Bari</surname><given-names>A</given-names></name>, <name><surname>Aston-Jones</surname><given-names>G</given-names></name>. <article-title>Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons</article-title>. <source>Neuropharmacology</source>. <year>2013</year>;<volume>64</volume>: <fpage>53</fpage>–<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.07.020</pub-id>
<?supplied-pmid 22820275?><pub-id pub-id-type="pmid">22820275</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref080">
                <label>80</label>
                <mixed-citation publication-type="journal"><name><surname>Eldar</surname><given-names>E</given-names></name>, <name><surname>Cohen</surname><given-names>JD</given-names></name>, <name><surname>Niv</surname><given-names>Y</given-names></name>. <article-title>The effects of neural gain on attention and learning</article-title>. <source>Nat Neurosci</source>. <year>2013</year>;<volume>16</volume>: <fpage>1146</fpage>–<lpage>1153</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn.3428</pub-id>
<?supplied-pmid 23770566?><pub-id pub-id-type="pmid">23770566</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref081">
                <label>81</label>
                <mixed-citation publication-type="journal"><name><surname>Hauser</surname><given-names>TU</given-names></name>, <name><surname>Allen</surname><given-names>M</given-names></name>, <name><surname>Purg</surname><given-names>N</given-names></name>, <name><surname>Moutoussis</surname><given-names>M</given-names></name>, <name><surname>Rees</surname><given-names>G</given-names></name>, <name><surname>Dolan</surname><given-names>RJ</given-names></name>. <article-title>Noradrenaline blockade specifically enhances metacognitive performance</article-title>. <source>eLife</source>. <year>2017</year>;<volume>6</volume>: <fpage>e24901</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7554/eLife.24901</pub-id><?supplied-pmid 28489001?><pub-id pub-id-type="pmid">28489001</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref082">
                <label>82</label>
                <mixed-citation publication-type="journal"><name><surname>Behrens</surname><given-names>TEJ</given-names></name>, <name><surname>Woolrich</surname><given-names>MW</given-names></name>, <name><surname>Walton</surname><given-names>ME</given-names></name>, <name><surname>Rushworth</surname><given-names>MFS</given-names></name>. <article-title>Learning the value of information in an uncertain world</article-title>. <source>Nat Neurosci</source>. <year>2007</year>;<volume>10</volume>: <fpage>1214</fpage>–<lpage>1221</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn1954</pub-id>
<?supplied-pmid 17676057?><pub-id pub-id-type="pmid">17676057</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref083">
                <label>83</label>
                <mixed-citation publication-type="journal"><name><surname>McGuire</surname><given-names>JT</given-names></name>, <name><surname>Nassar</surname><given-names>MR</given-names></name>, <name><surname>Gold</surname><given-names>JI</given-names></name>, <name><surname>Kable</surname><given-names>JW</given-names></name>. <article-title>Functionally Dissociable Influences on Learning Rate in a Dynamic Environment</article-title>. <source>Neuron</source>. <year>2014</year>;<volume>84</volume>: <fpage>870</fpage>–<lpage>881</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuron.2014.10.013</pub-id>
<?supplied-pmid 25459409?><pub-id pub-id-type="pmid">25459409</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref084">
                <label>84</label>
                <mixed-citation publication-type="journal"><name><surname>O’Reilly</surname><given-names>JX</given-names></name>, <name><surname>Schuffelgen</surname><given-names>U</given-names></name>, <name><surname>Cuell</surname><given-names>SF</given-names></name>, <name><surname>Behrens</surname><given-names>TEJ</given-names></name>, <name><surname>Mars</surname><given-names>RB</given-names></name>, <name><surname>Rushworth</surname><given-names>MFS</given-names></name>. <article-title>Dissociable effects of surprise and model update in parietal and anterior cingulate cortex</article-title>. <source>Proc Natl Acad Sci</source>. <year>2013</year>;<volume>110</volume>: <fpage>E3660</fpage>–<lpage>E3669</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1305373110</pub-id>
<?supplied-pmid 23986499?><pub-id pub-id-type="pmid">23986499</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref085">
                <label>85</label>
                <mixed-citation publication-type="journal"><name><surname>Arnsten</surname><given-names>AFT</given-names></name>, <name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name>. <article-title>Selective prefrontal cortical projections to the region of the locus coeruleus and raphe nuclei in the rhesus monkey</article-title>. <source>Brain Res</source>. <year>1984</year>;<volume>306</volume>: <fpage>9</fpage>–<lpage>18</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0006-8993(84)90351-2</pub-id>
<?supplied-pmid 6466989?><pub-id pub-id-type="pmid">6466989</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref086">
                <label>86</label>
                <mixed-citation publication-type="journal"><name><surname>Tervo</surname><given-names>DGR</given-names></name>, <name><surname>Proskurin</surname><given-names>M</given-names></name>, <name><surname>Manakov</surname><given-names>M</given-names></name>, <name><surname>Kabra</surname><given-names>M</given-names></name>, <name><surname>Vollmer</surname><given-names>A</given-names></name>, <name><surname>Branson</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Behavioral Variability through Stochastic Choice and Its Gating by Anterior Cingulate Cortex</article-title>. <source>Cell</source>. <year>2014</year>;<volume>159</volume>: <fpage>21</fpage>–<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.037</pub-id>
<?supplied-pmid 25259917?><pub-id pub-id-type="pmid">25259917</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref087">
                <label>87</label>
                <mixed-citation publication-type="journal"><name><surname>Pifl</surname><given-names>C</given-names></name>, <name><surname>Kish</surname><given-names>SJ</given-names></name>, <name><surname>Hornykiewicz</surname><given-names>O</given-names></name>. <article-title>Thalamic noradrenaline in Parkinson’s disease: Deficits suggest role in motor and non-motor symptoms</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>: <fpage>1618</fpage>–<lpage>1624</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.25109</pub-id>
<?supplied-pmid 23038412?><pub-id pub-id-type="pmid">23038412</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref088">
                <label>88</label>
                <mixed-citation publication-type="journal"><name><surname>Scatton</surname><given-names>B</given-names></name>, <name><surname>Javoy-Agid</surname><given-names>F</given-names></name>, <name><surname>Rouquier</surname><given-names>L</given-names></name>, <name><surname>Dubois</surname><given-names>B</given-names></name>, <name><surname>Agid</surname><given-names>Y</given-names></name>. <article-title>Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease</article-title>. <source>Brain Res</source>. <year>1983</year>;<volume>275</volume>: <fpage>321</fpage>–<lpage>328</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0006-8993(83)90993-9</pub-id>
<?supplied-pmid 6626985?><pub-id pub-id-type="pmid">6626985</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref089">
                <label>89</label>
                <mixed-citation publication-type="journal"><name><surname>Bymaster</surname><given-names>FP</given-names></name>, <name><surname>Katner</surname><given-names>JS</given-names></name>, <name><surname>Nelson</surname><given-names>DL</given-names></name>, <name><surname>Hemrick-Luecke</surname><given-names>SK</given-names></name>, <name><surname>Threlkeld</surname><given-names>PG</given-names></name>, <name><surname>Heiligenstein</surname><given-names>JH</given-names></name>, <etal>et al</etal>. <article-title>Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder</article-title>. <source>Neuropsychopharmacology</source>. <year>2002</year>;<volume>27</volume>: <fpage>699</fpage>–<lpage>711</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0893-133X(02)00346-9</pub-id>
<?supplied-pmid 12431845?><pub-id pub-id-type="pmid">12431845</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref090">
                <label>90</label>
                <mixed-citation publication-type="journal"><name><surname>Swanson</surname><given-names>CJ</given-names></name>, <name><surname>Perry</surname><given-names>KW</given-names></name>, <name><surname>Koch-Krueger</surname><given-names>S</given-names></name>, <name><surname>Katner</surname><given-names>J</given-names></name>, <name><surname>Svensson</surname><given-names>KA</given-names></name>, <name><surname>Bymaster</surname><given-names>FP</given-names></name>. <article-title>Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat</article-title>. <source>Neuropharmacology</source>. <year>2006</year>;<volume>50</volume>: <fpage>755</fpage>–<lpage>760</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.11.022</pub-id>
<?supplied-pmid 16427661?><pub-id pub-id-type="pmid">16427661</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref091">
                <label>91</label>
                <mixed-citation publication-type="journal"><name><surname>Huys</surname><given-names>QJM</given-names></name>, <name><surname>Maia</surname><given-names>TV</given-names></name>, <name><surname>Frank</surname><given-names>MJ</given-names></name>. <article-title>Computational psychiatry as a bridge from neuroscience to clinical applications</article-title>. <source>Nat Neurosci</source>. <year>2016</year>;<volume>19</volume>: <fpage>404</fpage>–<lpage>413</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn.4238</pub-id>
<?supplied-pmid 26906507?><pub-id pub-id-type="pmid">26906507</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref092">
                <label>92</label>
                <mixed-citation publication-type="journal"><name><surname>Yarkoni</surname><given-names>T</given-names></name>, <name><surname>Westfall</surname><given-names>J</given-names></name>. <article-title>Choosing Prediction Over Explanation in Psychology: Lessons From Machine Learning</article-title>. <source>Perspect Psychol Sci.</source><year>2017</year>;<volume>12</volume>: <fpage>1100</fpage>–<lpage>1122</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1745691617693393</pub-id>
<?supplied-pmid 28841086?><pub-id pub-id-type="pmid">28841086</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref093">
                <label>93</label>
                <mixed-citation publication-type="journal"><name><surname>Cuthbert</surname><given-names>BN</given-names></name>, <name><surname>Insel</surname><given-names>TR</given-names></name>. <article-title>Toward the future of psychiatric diagnosis: the seven pillars of RDoC</article-title>. <source>BMC Med.</source><year>2013</year>;<fpage>11</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1741-7015-11-11</pub-id><?supplied-pmid 23324495?><pub-id pub-id-type="pmid">23324495</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref094">
                <label>94</label>
                <mixed-citation publication-type="journal"><name><surname>Sesack</surname><given-names>SR</given-names></name>, <name><surname>Hawrylak</surname><given-names>VA</given-names></name>, <name><surname>Matus</surname><given-names>C</given-names></name>, <name><surname>Guido</surname><given-names>MA</given-names></name>, <name><surname>Levey</surname><given-names>AI</given-names></name>. <article-title>Dopamine Axon Varicosities in the Prelimbic Division of the Rat Prefrontal Cortex Exhibit Sparse Immunoreactivity for the Dopamine Transporter</article-title>. <source>J Neurosci</source>. <year>1998</year>;<volume>18</volume>: <fpage>2697</fpage>–<lpage>2708</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.18-07-02697.1998</pub-id>
<?supplied-pmid 9502827?><pub-id pub-id-type="pmid">9502827</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref095">
                <label>95</label>
                <mixed-citation publication-type="journal"><name><surname>Wayment</surname><given-names>HK</given-names></name>, <name><surname>Schenk</surname><given-names>JO</given-names></name>, <name><surname>Sorg</surname><given-names>BA</given-names></name>. <article-title>Characterization of Extracellular Dopamine Clearance in the Medial Prefrontal Cortex: Role of Monoamine Uptake and Monoamine Oxidase Inhibition</article-title>. <source>J Neurosci</source>. <year>2001</year>;<volume>21</volume>: <fpage>35</fpage>–<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-01-00035.2001</pub-id>
<?supplied-pmid 11150317?><pub-id pub-id-type="pmid">11150317</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref096">
                <label>96</label>
                <mixed-citation publication-type="journal"><name><surname>Seamans</surname><given-names>JK</given-names></name>, <name><surname>Yang</surname><given-names>CR</given-names></name>. <article-title>The principal features and mechanisms of dopamine modulation in the prefrontal cortex</article-title>. <source>Prog Neurobiol</source>. <year>2004</year>;<volume>74</volume>: <fpage>1</fpage>–<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pneurobio.2004.05.006</pub-id>
<?supplied-pmid 15381316?><pub-id pub-id-type="pmid">15381316</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref097">
                <label>97</label>
                <mixed-citation publication-type="journal"><name><surname>Devoto</surname><given-names>P</given-names></name>, <name><surname>Flore</surname><given-names>G</given-names></name>. <article-title>On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?</article-title><source>Curr Neuropharmacol.</source><year>2006</year>;<volume>4</volume>: <fpage>115</fpage>–<lpage>125</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/157015906776359559</pub-id>
<?supplied-pmid 18615131?><pub-id pub-id-type="pmid">18615131</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref098">
                <label>98</label>
                <mixed-citation publication-type="journal"><name><surname>Devoto</surname><given-names>P</given-names></name>, <name><surname>Flore</surname><given-names>G</given-names></name>, <name><surname>Pani</surname><given-names>L</given-names></name>, <name><surname>Gessa</surname><given-names>GL</given-names></name>. <article-title>Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex</article-title>. <source>Mol Psychiatry</source>. <year>2001</year>;<volume>6</volume>: <fpage>657</fpage>–<lpage>664</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/sj.mp.4000904</pub-id>
<?supplied-pmid 11673793?><pub-id pub-id-type="pmid">11673793</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref099">
                <label>99</label>
                <mixed-citation publication-type="journal"><name><surname>Devoto</surname><given-names>P</given-names></name>, <name><surname>Flore</surname><given-names>G</given-names></name>, <name><surname>Saba</surname><given-names>P</given-names></name>, <name><surname>Fa</surname><given-names>M</given-names></name>, <name><surname>Gessa</surname><given-names>GL</given-names></name>. <article-title>Stimulation of the locus coeruleus elicits noradrenaline and dopamine release in the medial prefrontal and parietal cortex</article-title>. <source>J Neurochem</source>. <year>2005</year>;<volume>92</volume>: <fpage>368</fpage>–<lpage>374</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02866.x</pub-id>
<?supplied-pmid 15663484?><pub-id pub-id-type="pmid">15663484</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref100">
                <label>100</label>
                <mixed-citation publication-type="journal"><name><surname>Mejias-Aponte</surname><given-names>CA</given-names></name>. <article-title>Specificity and impact of adrenergic projections to the midbrain dopamine system</article-title>. <source>Brain Res</source>. <year>2016</year>;<volume>1641</volume>: <fpage>258</fpage>–<lpage>273</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.brainres.2016.01.036</pub-id>
<?supplied-pmid 26820641?><pub-id pub-id-type="pmid">26820641</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref101">
                <label>101</label>
                <mixed-citation publication-type="journal"><name><surname>Duszkiewicz</surname><given-names>AJ</given-names></name>, <name><surname>McNamara</surname><given-names>CG</given-names></name>, <name><surname>Takeuchi</surname><given-names>T</given-names></name>, <name><surname>Genzel</surname><given-names>L</given-names></name>. <article-title>Novelty and Dopaminergic Modulation of Memory Persistence: A Tale of Two Systems</article-title>. <source>Trends Neurosci</source>. <year>2019</year>;<volume>42</volume>: <fpage>102</fpage>–<lpage>114</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tins.2018.10.002</pub-id>
<?supplied-pmid 30455050?><pub-id pub-id-type="pmid">30455050</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref102">
                <label>102</label>
                <mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>Z</given-names></name>, <name><surname>Altena</surname><given-names>E</given-names></name>, <name><surname>Nombela</surname><given-names>C</given-names></name>, <name><surname>Housden</surname><given-names>CR</given-names></name>, <name><surname>Maxwell</surname><given-names>H</given-names></name>, <name><surname>Rittman</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Improving Response Inhibition in Parkinson’s Disease with Atomoxetine</article-title>. <source>Biol Psychiatry</source>. <year>2015</year>;<volume>77</volume>: <fpage>740</fpage>–<lpage>748</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2014.01.024</pub-id>
<?supplied-pmid 24655598?><pub-id pub-id-type="pmid">24655598</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref103">
                <label>103</label>
                <mixed-citation publication-type="journal"><name><surname>Berridge</surname><given-names>CW</given-names></name>, <name><surname>Waterhouse</surname><given-names>BD</given-names></name>. <article-title>The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes</article-title>. <source>Brain Res Rev</source>. <year>2003</year>;<volume>42</volume>: <fpage>33</fpage>–<lpage>84</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0165-0173(03)00143-7</pub-id>
<?supplied-pmid 12668290?><pub-id pub-id-type="pmid">12668290</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref104">
                <label>104</label>
                <mixed-citation publication-type="journal"><name><surname>Toschi</surname><given-names>C</given-names></name>, <name><surname>Hervig</surname><given-names>ME-S</given-names></name>, <name><surname>Moazen</surname><given-names>P</given-names></name>, <name><surname>Parker</surname><given-names>MG</given-names></name>, <name><surname>Dalley</surname><given-names>JW</given-names></name>, <name><surname>Gether</surname><given-names>U</given-names></name>, <etal>et al</etal>. <article-title>Adaptive aspects of impulsivity and interactions with effects of catecholaminergic agents in the 5-choice serial reaction time task: implications for ADHD</article-title>. <source>Psychopharmacology (Berl).</source><year>2021</year> [cited 23 Jun 2021]. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00213-021-05883-y</pub-id>
<?supplied-pmid 34104987?><pub-id pub-id-type="pmid">34104987</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref105">
                <label>105</label>
                <mixed-citation publication-type="journal"><name><surname>Aitchison</surname><given-names>L</given-names></name>, <name><surname>Lengyel</surname><given-names>M</given-names></name>. <article-title>With or without you: predictive coding and Bayesian inference in the brain</article-title>. <source>Curr Opin Neurobiol</source>. <year>2017</year>;<volume>46</volume>: <fpage>219</fpage>–<lpage>227</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.conb.2017.08.010</pub-id>
<?supplied-pmid 28942084?><pub-id pub-id-type="pmid">28942084</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref106">
                <label>106</label>
                <mixed-citation publication-type="journal"><name><surname>Kocagoncu</surname><given-names>E</given-names></name>, <name><surname>Klimovich-Gray</surname><given-names>A</given-names></name>, <name><surname>Hughes</surname><given-names>LE</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>Evidence and implications of abnormal predictive coding in dementia</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>: <fpage>3311</fpage>–<lpage>3321</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/brain/awab254</pub-id>
<?supplied-pmid 34240109?><pub-id pub-id-type="pmid">34240109</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref107">
                <label>107</label>
                <mixed-citation publication-type="journal"><name><surname>Pezzulo</surname><given-names>G</given-names></name>, <name><surname>Rigoli</surname><given-names>F</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>Hierarchical Active Inference: A Theory of Motivated Control</article-title>. <source>Trends Cogn Sci.</source><year>2018</year>;<volume>22</volume>: <fpage>294</fpage>–<lpage>306</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.tics.2018.01.009</pub-id>
<?supplied-pmid 29475638?><pub-id pub-id-type="pmid">29475638</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref108">
                <label>108</label>
                <mixed-citation publication-type="journal"><name><surname>Badre</surname><given-names>D</given-names></name>, <name><surname>D’Esposito</surname><given-names>M</given-names></name>. <article-title>Is the rostro-caudal axis of the frontal lobe hierarchical?</article-title><source>Nat Rev Neurosci</source>. <year>2009</year>;<volume>10</volume>: <fpage>659</fpage>–<lpage>669</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nrn2667</pub-id>
<?supplied-pmid 19672274?><pub-id pub-id-type="pmid">19672274</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref109">
                <label>109</label>
                <mixed-citation publication-type="journal"><name><surname>Hasson</surname><given-names>U</given-names></name>, <name><surname>Yang</surname><given-names>E</given-names></name>, <name><surname>Vallines</surname><given-names>I</given-names></name>, <name><surname>Heeger</surname><given-names>DJ</given-names></name>, <name><surname>Rubin</surname><given-names>N</given-names></name>. <article-title>A Hierarchy of Temporal Receptive Windows in Human Cortex</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>: <fpage>2539</fpage>–<lpage>2550</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5487-07.2008</pub-id>
<?supplied-pmid 18322098?><pub-id pub-id-type="pmid">18322098</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref110">
                <label>110</label>
                <mixed-citation publication-type="journal"><name><surname>Kiebel</surname><given-names>SJ</given-names></name>, <name><surname>Daunizeau</surname><given-names>J</given-names></name>, <name><surname>Friston</surname><given-names>KJ</given-names></name>. <article-title>A Hierarchy of Time-Scales and the Brain.</article-title><name><surname>Sporns</surname><given-names>O</given-names></name>, editor. <source>PLoS Comput Biol.</source><year>2008</year>;<volume>4</volume>: <fpage>e1000209</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1000209</pub-id><?supplied-pmid 19008936?><pub-id pub-id-type="pmid">19008936</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref111">
                <label>111</label>
                <mixed-citation publication-type="journal"><name><surname>Koechlin</surname><given-names>E.</given-names></name><article-title>The Architecture of Cognitive Control in the Human Prefrontal Cortex</article-title>. <source>Science</source>. <year>2003</year>;<volume>302</volume>: <fpage>1181</fpage>–<lpage>1185</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1088545</pub-id>
<?supplied-pmid 14615530?><pub-id pub-id-type="pmid">14615530</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref112">
                <label>112</label>
                <mixed-citation publication-type="book"><name><surname>Chong</surname><given-names>TT-J</given-names></name>, <name><surname>Bonnelle</surname><given-names>V</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>. <part-title>Chapter 4—Quantifying motivation with effort-based decision-making paradigms in health and disease</part-title>. In: <name><surname>Studer</surname><given-names>B</given-names></name>, <name><surname>Knecht</surname><given-names>S</given-names></name>, editors. <source>Progress in Brain Research</source>. <publisher-name>Elsevier</publisher-name>; <year>2016</year>. pp. <fpage>71</fpage>–<lpage>100</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/bs.pbr.2016.05.002</pub-id>
<?supplied-pmid 27926453?></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref113">
                <label>113</label>
                <mixed-citation publication-type="journal"><name><surname>Husain</surname><given-names>M</given-names></name>, <name><surname>Roiser</surname><given-names>JP</given-names></name>. <article-title>Neuroscience of apathy and anhedonia: a transdiagnostic approach</article-title>. <source>Nat Rev Neurosci</source>. <year>2018</year>;<volume>19</volume>: <fpage>470</fpage>–<lpage>484</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41583-018-0029-9</pub-id>
<?supplied-pmid 29946157?><pub-id pub-id-type="pmid">29946157</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref114">
                <label>114</label>
                <mixed-citation publication-type="journal"><name><surname>Salamone</surname><given-names>JD</given-names></name>, <name><surname>Correa</surname><given-names>M</given-names></name>. <article-title>The Mysterious Motivational Functions of Mesolimbic Dopamine</article-title>. <source>Neuron</source>. <year>2012</year>;<volume>76</volume>: <fpage>470</fpage>–<lpage>485</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuron.2012.10.021</pub-id>
<?supplied-pmid 23141060?><pub-id pub-id-type="pmid">23141060</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref115">
                <label>115</label>
                <mixed-citation publication-type="journal"><name><surname>Müller</surname><given-names>T</given-names></name>, <name><surname>Klein-Flügge</surname><given-names>MC</given-names></name>, <name><surname>Manohar</surname><given-names>SG</given-names></name>, <name><surname>Husain</surname><given-names>M</given-names></name>, <name><surname>Apps</surname><given-names>MAJ</given-names></name>. <article-title>Neural and computational mechanisms of momentary fatigue and persistence in effort-based choice</article-title>. <source>Nat Commun.</source><year>2021</year>;<volume>12</volume>: <fpage>4593</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-021-24927-7</pub-id><?supplied-pmid 34321478?><pub-id pub-id-type="pmid">34321478</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref116">
                <label>116</label>
                <mixed-citation publication-type="journal"><name><surname>Emre</surname><given-names>M</given-names></name>, <name><surname>Aarsland</surname><given-names>D</given-names></name>, <name><surname>Brown</surname><given-names>RG</given-names></name>, <name><surname>Burn</surname><given-names>DJ</given-names></name>, <name><surname>Duyckaerts</surname><given-names>C</given-names></name>, <name><surname>Mizuno</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Clinical diagnostic criteria for dementia associated with Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2007</year>;<volume>22</volume>: <fpage>1689</fpage>–<lpage>1707</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.21507</pub-id>
<?supplied-pmid 17542011?><pub-id pub-id-type="pmid">17542011</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref117">
                <label>117</label>
                <mixed-citation publication-type="journal"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name>, <name><surname>Falup-Pecurariu</surname><given-names>C</given-names></name>, <name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name>, <name><surname>Serrano-Dueñas</surname><given-names>M</given-names></name>, <name><surname>Carod Artal</surname><given-names>FJ</given-names></name>, <name><surname>Rojo Abuin</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>Dementia associated with Parkinson’s disease: Applying the Movement Disorder Society Task Force criteria</article-title>. <source>Parkinsonism Relat Disord</source>. <year>2011</year>;<volume>17</volume>: <fpage>621</fpage>–<lpage>624</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.parkreldis.2011.05.017</pub-id>
<?supplied-pmid 21684792?><pub-id pub-id-type="pmid">21684792</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref118">
                <label>118</label>
                <mixed-citation publication-type="journal"><name><surname>Weintraub</surname><given-names>D</given-names></name>, <name><surname>Hoops</surname><given-names>S</given-names></name>, <name><surname>Shea</surname><given-names>JA</given-names></name>, <name><surname>Lyons</surname><given-names>KE</given-names></name>, <name><surname>Pahwa</surname><given-names>R</given-names></name>, <name><surname>Driver-Dunckley</surname><given-names>ED</given-names></name>, <etal>et al</etal>. <article-title>Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>: <fpage>1461</fpage>–<lpage>1467</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.22571</pub-id>
<?supplied-pmid 19452562?><pub-id pub-id-type="pmid">19452562</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref119">
                <label>119</label>
                <mixed-citation publication-type="journal"><name><surname>Hinson</surname><given-names>VK</given-names></name>, <name><surname>Delambo</surname><given-names>A</given-names></name>, <name><surname>Elm</surname><given-names>J</given-names></name>, <name><surname>Turner</surname><given-names>T</given-names></name>. <article-title>A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson’s Disease</article-title>. <source>Mov Disord Clin Pract</source>. <year>2017</year>;<volume>4</volume>: <fpage>416</fpage>–<lpage>423</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mdc3.12455</pub-id>
<?supplied-pmid 30363371?><pub-id pub-id-type="pmid">30363371</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref120">
                <label>120</label>
                <mixed-citation publication-type="journal"><name><surname>Weintraub</surname><given-names>D</given-names></name>, <name><surname>Mavandadi</surname><given-names>S</given-names></name>, <name><surname>Mamikonyan</surname><given-names>E</given-names></name>, <name><surname>Siderowf</surname><given-names>AD</given-names></name>, <name><surname>Duda</surname><given-names>JE</given-names></name>, <name><surname>Hurtig</surname><given-names>HI</given-names></name>, <etal>et al</etal>. <article-title>Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>75</volume>: <fpage>448</fpage>–<lpage>455</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181ebdd79</pub-id>
<?supplied-pmid 20679638?><pub-id pub-id-type="pmid">20679638</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref121">
                <label>121</label>
                <mixed-citation publication-type="journal"><name><surname>Sauer</surname><given-names>J-M</given-names></name>, <name><surname>Ring</surname><given-names>BJ</given-names></name>, <name><surname>Witcher</surname><given-names>JW</given-names></name>. <article-title>Clinical pharmacokinetics of atomoxetine.</article-title><source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>: <fpage>571</fpage>–<lpage>590</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2165/00003088-200544060-00002</pub-id>
<?supplied-pmid 15910008?><pub-id pub-id-type="pmid">15910008</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref122">
                <label>122</label>
                <mixed-citation publication-type="journal"><name><surname>Teichert</surname><given-names>J</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>, <name><surname>Ersche</surname><given-names>KD</given-names></name>, <name><surname>Skandali</surname><given-names>N</given-names></name>, <name><surname>Sacher</surname><given-names>J</given-names></name>, <name><surname>Aigner</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies</article-title>. <source>Int J Clin Pharmacol Ther</source>. <year>2020</year>;<volume>58</volume>: <fpage>426</fpage>–<lpage>438</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5414/CP203705</pub-id>
<?supplied-pmid 32449675?><pub-id pub-id-type="pmid">32449675</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref123">
                <label>123</label>
                <mixed-citation publication-type="journal"><name><surname>Körding</surname><given-names>KP</given-names></name>, <name><surname>Wolpert</surname><given-names>DM</given-names></name>. <article-title>Bayesian integration in sensorimotor learning</article-title>. <source>Nature</source>. <year>2004</year>;<volume>427</volume>: <fpage>244</fpage>–<lpage>247</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature02169</pub-id>
<?supplied-pmid 14724638?><pub-id pub-id-type="pmid">14724638</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref124">
                <label>124</label>
                <mixed-citation publication-type="journal"><name><surname>Pouget</surname><given-names>A</given-names></name>, <name><surname>Beck</surname><given-names>JM</given-names></name>, <name><surname>Ma</surname><given-names>WJ</given-names></name>, <name><surname>Latham</surname><given-names>PE</given-names></name>. <article-title>Probabilistic brains: knowns and unknowns</article-title>. <source>Nat Neurosci</source>. <year>2013</year>;<volume>16</volume>: <fpage>1170</fpage>–<lpage>1178</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nn.3495</pub-id>
<?supplied-pmid 23955561?><pub-id pub-id-type="pmid">23955561</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref125">
                <label>125</label>
                <mixed-citation publication-type="journal"><name><surname>Xiang</surname><given-names>Y</given-names></name>, <name><surname>Graeber</surname><given-names>T</given-names></name>, <name><surname>Enke</surname><given-names>B</given-names></name>, <name><surname>Gershman</surname><given-names>SJ</given-names></name>. <article-title>Confidence and central tendency in perceptual judgment</article-title>. <source>Atten Percept Psychophys.</source><year>2021</year> [cited 28 Apr 2021]. <comment>doi: </comment><pub-id pub-id-type="doi">10.3758/s13414-021-02300-6</pub-id>
<?supplied-pmid 33890239?><pub-id pub-id-type="pmid">33890239</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref126">
                <label>126</label>
                <mixed-citation publication-type="journal"><name><surname>Wolpe</surname><given-names>N</given-names></name>, <name><surname>Nombela</surname><given-names>C</given-names></name>, <name><surname>Rowe</surname><given-names>JB</given-names></name>. <article-title>Dopaminergic modulation of positive expectations for goal-directed action: evidence from Parkinson’s disease</article-title>. <source>Front Psychol.</source><year>2015</year>;<fpage>6</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fpsyg.2015.00006</pub-id><?supplied-pmid 25759672?><pub-id pub-id-type="pmid">25759672</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref127">
                <label>127</label>
                <mixed-citation publication-type="journal"><name><surname>Vehtari</surname><given-names>A</given-names></name>, <name><surname>Gelman</surname><given-names>A</given-names></name>, <name><surname>Gabry</surname><given-names>J</given-names></name>. <article-title>Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC.</article-title><source>Stat Comput.</source><year>2017</year>;<volume>27</volume>: <fpage>1413</fpage>–<lpage>1432</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11222-016-9696-4</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref128">
                <label>128</label>
                <mixed-citation publication-type="journal"><name><surname>Priovoulos</surname><given-names>N</given-names></name>, <name><surname>Jacobs</surname><given-names>HIL</given-names></name>, <name><surname>Ivanov</surname><given-names>D</given-names></name>, <name><surname>Uludag</surname><given-names>K</given-names></name>, <name><surname>Verhey</surname><given-names>FRJ</given-names></name>, <name><surname>Poser</surname><given-names>BA</given-names></name>. <article-title>High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T</article-title>. <source>NeuroImage</source>. <year>2018</year>;<volume>168</volume>: <fpage>427</fpage>–<lpage>436</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.07.045</pub-id>
<?supplied-pmid 28743460?><pub-id pub-id-type="pmid">28743460</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref129">
                <label>129</label>
                <mixed-citation publication-type="journal"><name><surname>Fonov</surname><given-names>V</given-names></name>, <name><surname>Evans</surname><given-names>AC</given-names></name>, <name><surname>Botteron</surname><given-names>K</given-names></name>, <name><surname>Almli</surname><given-names>CR</given-names></name>, <name><surname>McKinstry</surname><given-names>RC</given-names></name>, <name><surname>Collins</surname><given-names>DL</given-names></name>. <article-title>Unbiased average age-appropriate atlases for pediatric studies.</article-title><source>NeuroImage</source>. <year>2011</year>;<volume>54</volume>: <fpage>313</fpage>–<lpage>327</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.07.033</pub-id>
<?supplied-pmid 20656036?><pub-id pub-id-type="pmid">20656036</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref130">
                <label>130</label>
                <mixed-citation publication-type="journal"><name><surname>Hinne</surname><given-names>M</given-names></name>, <name><surname>Gronau</surname><given-names>QF</given-names></name>, <name><surname>van den Bergh</surname><given-names>D</given-names></name>, <name><surname>Wagenmakers</surname><given-names>E-J</given-names></name>. <article-title>A Conceptual Introduction to Bayesian Model Averaging.</article-title><source>Adv Methods Pract Psychol Sci.</source><year>2020</year>; 2515245919898657. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/2515245919898657</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref131">
                <label>131</label>
                <mixed-citation publication-type="journal"><name><surname>Kleiner</surname><given-names>M</given-names></name>, <name><surname>Brainard</surname><given-names>D</given-names></name>, <name><surname>Pelli</surname><given-names>D</given-names></name>. <article-title>What’s new in Psychtoolbox-3? Arezzo, Italy: 30th European Conference on Visual Perception</article-title>; <year>2007</year>.</mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref132">
                <label>132</label>
                <mixed-citation publication-type="journal"><name><surname>Tustison</surname><given-names>NJ</given-names></name>, <name><surname>Cook</surname><given-names>PA</given-names></name>, <name><surname>Klein</surname><given-names>A</given-names></name>, <name><surname>Song</surname><given-names>G</given-names></name>, <name><surname>Das</surname><given-names>SR</given-names></name>, <name><surname>Duda</surname><given-names>JT</given-names></name>, <etal>et al</etal>. <article-title>Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements</article-title>. <source>NeuroImage</source>. <year>2014</year>;<volume>99</volume>: <fpage>166</fpage>–<lpage>179</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.neuroimage.2014.05.044</pub-id>
<?supplied-pmid 24879923?><pub-id pub-id-type="pmid">24879923</pub-id></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref133">
                <label>133</label>
                <mixed-citation publication-type="book"><collab>R Core Team</collab>. <part-title>R: A Language and Environment for Statistical Computing</part-title>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>; <year>2019</year>. Available: <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></mixed-citation>
              </ref>
              <ref id="pcbi.1010079.ref134">
                <label>134</label>
                <mixed-citation publication-type="journal"><name><surname>Carpenter</surname><given-names>B</given-names></name>, <name><surname>Gelman</surname><given-names>A</given-names></name>, <name><surname>Hoffman</surname><given-names>MD</given-names></name>, <name><surname>Lee</surname><given-names>D</given-names></name>, <name><surname>Goodrich</surname><given-names>B</given-names></name>, <name><surname>Betancourt</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Stan: A Probabilistic Programming Language</article-title>. <source>J Stat Softw.</source><year>2017</year>;<fpage>76</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.18637/jss.v076.i01</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article article-type="aggregated-review-documents" id="pcbi.1010079.r001" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1010079.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gershman</surname>
                    <given-names>Samuel J.</given-names>
                  </name>
                  <role>Deputy Editor</role>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahn</surname>
                    <given-names>Woo-Young</given-names>
                  </name>
                  <role>Associate Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Gershman, Ahn</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Gershman, Ahn</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010079" id="rel-obj001" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">9 Dec 2021</named-content>
              </p>
              <p>Dear Dr. Hezemans,</p>
              <p>Thank you very much for submitting your manuscript "Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes" for consideration at PLOS Computational Biology. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by three independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.</p>
              <p>Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.</p>
              <p>When you are ready to resubmit, please upload the following:</p>
              <p>[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out</p>
              <p>[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).</p>
              <p>Important additional instructions are given below your reviewer comments.</p>
              <p>Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.</p>
              <p>Sincerely,</p>
              <p>Woo-Young Ahn</p>
              <p>Associate Editor</p>
              <p>PLOS Computational Biology</p>
              <p>Samuel Gershman</p>
              <p>Deputy Editor</p>
              <p>PLOS Computational Biology</p>
              <p>***********************</p>
              <p>A link appears below if there are any accompanying review attachments. If you believe any reviews to be missing, please contact <email>ploscompbiol@plos.org</email> immediately:</p>
              <p>[LINK]</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Authors:</bold>
              </p>
              <p>Reviewer #1: This is an interesting study in which the authors use a clever task that allows them to distinguish subjects' precision of their prior expectations (about a target's movement) from the precision of the sensory likelihood (from the applied force to the target). They collect data from n=17 Parkinson's patients and controls; the former are also given Atomoxetine and placebo in a within-subject manipulation, and 7T imaging of their Locus Coereleus. The authors found a negative correlation between prior/likelihood weighting and apathy, and an interaction such that subjects with lower LC integrity showed a positive effect of ATO on this weighting (higher LC integrity resulted in a negative effect). They are careful to control for other factors, which do not affect the results.</p>
              <p>Overall the topic is interesting and clinically important, and the methods are rigorous. There are some weaknesses: the main ones being that the sample size is fairly small (n=17), controls did not receive ATO or MRI scanning, Atomoxetine also has effects on DA as well as NA, and the PD patients were not any more apathetic than controls. This makes it difficult to draw firm conclusions about mechanisms of apathy in PD specifically. But the relationship of ATO effects on prior precision to LC integrity is certainly of interest. More detailed comments below:</p>
              <p>p15 - The authors are careful to say that these findings "suggest" a contributory mechanism to apathy in PD, but I think they should also explicitly stress that these PD patients were not apathetic - their apathy scores were no different to controls'. So this makes it difficult to extrapolate the findings to pathological levels of apathy. I would therefore rephrase the subsequent conclusion "this study provides evidence for a noradrenergic role in apathy in Parkinson’s disease".</p>
              <p>p3/16 - There seems to be a tension between some of the evidence about noradrenaline (NA). At the bottom of p3, lots of evidence is cited that NA relates to (phasic) unexpected uncertainty or (tonic) volatility in the environment, i.e. evidence that the model must be updated - hence priors should be weakened, in both cases. But how does this square with the finding that ATO increases the precision of priors, in those with a less intact LC? There is some rather intricate speculation in the Discussion about phasic/tonic LC firing ratios. But to me this indicates that the subjects with *intact* LC show the most intuitive result: that ATO *reduces* prior precision (as NA ought to if it encodes unexpected uncertainty). This makes me wonder whether the opposite ATO effects in those with less intact LC are in fact dopaminergic effects, unmasked by the impaired LC system? This makes more sense to me than positing an inverted-U or altered phasic/tonic relationships. Impossible to tell from this work of course, but I think this possibility should be mentioned a bit more clearly in line 430 or earlier.</p>
              <p>p22 - Can the authors explain a bit more why the 2x2 effort/reward manipulation was included if it was not being used? They just state "we did not analyse these factors further,</p>
              <p>following Hezemans et al. [43]" but this is a bit thin. E.g. why not check for an effect of Atomoxetine on these factors? Is there insufficient power with n=17 subjects?</p>
              <p>Small points</p>
              <p>p4 - I would frame the opposite of 'active' inference as perceptual inference, not 'passive' inference.</p>
              <p>Reviewer #2: I am grateful for the opportunity to review this excellent paper. I very much enjoyed reading it, and think this is a great example of computational neurology. It is difficult to find much to improve on, but there are a few points that would benefit from clarification:</p>
              <p>1. I thought the method for estimating the prior weighting based upon the slope between the two forms of error was very convincing in its simplicity. However, it would be useful to clarify whether this slope was calculated only for those trials in which the trajectory was not shown. I will assume this is the case in what follows. The reason this is important is that the sensory evidence is different between the conditions where the trajectory is and is not shown, and the performance error from those when it is cannot really be inserted into Equation 3, which computes the estimation error on the assumption of no visual trajectory data (the estimation will clear be different when visual data are available).</p>
              <p>2. Following from the above, could the author's comment on the sensory modalities assumed to contribute to the evidence? If not visual, I presume this will largely be tactile and proprioceptive data associated with the finger press. If so, this might be something the authors could make more of. As their focus is on a neurological condition often characterised as a movement disorder, it seems a very good experimental design that focuses on sensory modalities that result from self-generated movements.</p>
              <p>3. One difficulty is that the premise of this study is based upon apathy in Parkinson's disease, but it seems that the Parkinson's patients were no more apathetic than the controls. However, the authors highlight the association between locus coeruleus degeneration and apathy, and the interaction between prior weighting and the effect of pharmacological manipulations. Do the authors feel that this experiment could be practically adapted as a clinical test to identify potential responders to atomoxetine from a clinically heterogenous group?</p>
              <p>4. In Equation 5 - presumably the authors mean N(x^(n),sigma_s^2), not N(s^(n),sigma_s^2) for the likelihood? The likelihood should be a function of the latent parameters (i.e., the parameters described by the prior and posterior).</p>
              <p>Reviewer #3: Hezemans et al. present a study of 17 PD and 20 controls. The task was as per a previous study. Participants exerted a force to move a circle by a given distance on the screen, sometimes without feedback. When feedback is absent, they estimate how far they think they pushed the ball.</p>
              <p>The study shows that motivated people were biased to perceive their exerted force as being closer to the target.</p>
              <p>PD patients were given atomoxetine, which didn't change performance overall. However patients with MRI evidence of locus coeruleus degeneration showed stronger effects of drug on increasing the bias.</p>
              <p>The result is timely and novel. Noradrenergic degeneration in PD is of great clinical and scientific interest. Although the sample size is not huge, it appears to be a very clean sample of PD patients, and the analyses are rigorous, Bayesian, and well controlled. An impressive range of control analyses are presented.</p>
              <p>I had no major criticisms but I have a some comments on the interpretation.</p>
              <p>1) Comparison with other models of motivation.</p>
              <p>The framing of apathy in terms of active inference seems to make qualitatively different predictions to standard econometric theories. I think these should be highlighted, as many readers may not make the connections. In particular, the authors talk about "effort", but in their theory, there seems to be no asymmetry between exerting too much or too little force. Further, it seems a conceptual leap that a sensory prior that produces action, should translate to a prior over *perception* of action. Can the authors clarify why that should be? In general, I would appreciate more of an interface with existing theories of effort and apathy. Also, are the authors talking about physical or cognitive effort here?</p>
              <p>Accordingly an important negative seems to be that PD patients did not exert less force than healthy people, and that noradrenaline did not increase force (and perhaps apathy did not correlate with force either?). Does this inform theories of apathy?</p>
              <p>Further, the experimental design (effort x reward) was not analysed as such. Although this aligns with the previous paper, I believe that the reader would be genuinely interested in the effects of those manipulations, especially if they are null results. If the authors do not wish to report these, then are the data at least available?</p>
              <p>2) Intro - NA is presented as definitively signalling uncertainty. While there are reasonable arguments for this, I think some caution is wise in some of the stronger statements eg L88.</p>
              <p>3) I think "optimal" is used in an unusual way (page 8) - the authors write about the optimal integration, but this seems odd since the optimal prior actually has zero-weight (no precision). This is because the sensory input is not biased away from the target (I assume?) -- so it should always be "better" to use raw sensory information rather than integrate it with the target. People of course do mix the prior with evidence, but it is confusing to call this optimal.</p>
              <p>4) I would prefer if some of the task details in Materials &amp; Methods appeared up in the main text e.g. how the force determined the distance moved, the proportion of trials</p>
              <p>L225: a healthy</p>
              <p>**********</p>
              <p>
                <bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
              </p>
              <p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: <bold>No: </bold>Did not see it in text - maybe I missed it.</p>
              <p>**********</p>
              <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
              <p>Reviewer #3: <bold>Yes: </bold>Sanjay Manohar</p>
              <p>Figure Files:</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com" ext-link-type="uri">https://pacev2.apexcovantage.com</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email>figures@plos.org</email>.</p>
              <p>Data Requirements:</p>
              <p>Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: <ext-link xlink:href="http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5" ext-link-type="uri">http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5</ext-link>.</p>
              <p>Reproducibility:</p>
              <p>To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link></p>
              <p>References:</p>
              <p>Review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.</p>
              <p>
                <italic toggle="yes">If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</italic>
              </p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pcbi.1010079.r002">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1010079.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010079" id="rel-obj002" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">17 Feb 2022</named-content>
              </p>
              <supplementary-material id="pcbi.1010079.s012" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Hezemans_PLOS_CB_responseletter.docx</named-content></p>
                </caption>
                <media xlink:href="pcbi.1010079.s012.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pcbi.1010079.r003" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1010079.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gershman</surname>
                    <given-names>Samuel J.</given-names>
                  </name>
                  <role>Deputy Editor</role>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahn</surname>
                    <given-names>Woo-Young</given-names>
                  </name>
                  <role>Associate Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Gershman, Ahn</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Gershman, Ahn</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010079" id="rel-obj003" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">5 Apr 2022</named-content>
              </p>
              <p>Dear Dr. Hezemans,</p>
              <p>We are pleased to inform you that your manuscript 'Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes' has been provisionally accepted for publication in PLOS Computational Biology.</p>
              <p>Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.</p>
              <p>Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.</p>
              <p>IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.</p>
              <p>Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.</p>
              <p>Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. </p>
              <p>Best regards,</p>
              <p>Woo-Young Ahn</p>
              <p>Associate Editor</p>
              <p>PLOS Computational Biology</p>
              <p>Samuel Gershman</p>
              <p>Deputy Editor</p>
              <p>PLOS Computational Biology</p>
              <p>***********************************************************</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Authors:</bold>
              </p>
              <p>Reviewer #1: The authors have addressed all my concerns and I have no further comments. Compliments to them!</p>
              <p>Reviewer #2: I am grateful to the authors for their responses, and have no further edits to suggest. I am happy to endorse publication at this stage.</p>
              <p>Reviewer #3: The authors have responded to ask my comments most thoroughly. They should be congratulated on an excellent paper.</p>
              <p>**********</p>
              <p>
                <bold>Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?</bold>
              </p>
              <p>The <ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/materials-and-software-sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>Reviewer #3: Yes</p>
              <p>**********</p>
              <p>PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: No</p>
              <p>Reviewer #3: <bold>Yes: </bold>Sanjay Manohar</p>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pcbi.1010079.r004" specific-use="acceptance-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pcbi.1010079.r004</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gershman</surname>
                    <given-names>Samuel J.</given-names>
                  </name>
                  <role>Deputy Editor</role>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahn</surname>
                    <given-names>Woo-Young</given-names>
                  </name>
                  <role>Associate Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2022 Gershman, Ahn</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>Gershman, Ahn</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pcbi.1010079" id="rel-obj004" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">4 May 2022</named-content>
              </p>
              <p>PCOMPBIOL-D-21-01786R1 </p>
              <p>Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes</p>
              <p>Dear Dr Hezemans,</p>
              <p>I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.</p>
              <p>The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. </p>
              <p>Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.</p>
              <p>Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work! </p>
              <p>With kind regards,</p>
              <p>Olena Szabo</p>
              <p>PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom <email>ploscompbiol@plos.org</email> | Phone +44 (0) 1223-442824 | <ext-link xlink:href="http://ploscompbiol.org" ext-link-type="uri">ploscompbiol.org</ext-link> | @PLOSCompBiol</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
